{"study_id": 5911, "supplement_id": 977, "safety_score": "80", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to determine whether CBD could modulate psychophysiological responses, reduce alcohol craving and anxiety during cue exposure, and assess its tolerability in individuals with alcohol use disorder (AUD).", "results_summary": "CBD was associated with elevated parasympathetic nervous system activity, reduced self-reported anxiety during cue exposure, and decreased alcohol craving after cue exposure, without impairing executive function.", "population_specificity": "Non-treatment-seeking individuals with alcohol use disorder (AUD) (DSM-5 criteria).", "effective_dosage": "800 mg of CBD over 3 days.", "study_duration": "3 days.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:09:06.480257+00:00"}
{"study_id": 5910, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to investigate the neuroprotective effects of CBD in a retinal excitotoxicity model and develop a nanotechnological formulation to improve CBD delivery to the retina.", "results_summary": "CBD reversed AMPA-induced retinal damage, reduced inflammatory and oxidative stress markers, and the developed CBD-NLC3 formulation efficiently delivered CBD to the retina after topical administration.", "population_specificity": "Rats (in vivo model)", "effective_dosage": "10^-4 M CBD (intravitreal co-injection), CBD-NLC3 (topical administration)", "study_duration": "Not specified (single topical administration for CBD-NLC3)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:09:06.699044+00:00"}
{"study_id": 5914, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the stability and pharmaceutical properties of CBD in suppository formulations using different substrates (cocoa butter and Witepsol\u00ae H15) for rectal or vaginal administration.", "results_summary": "The study found no significant alterations in CBD content over 24 months, and suppositories with Witepsol\u00ae H15 showed superior release profiles compared to cocoa butter-based formulations. The disintegration and deformation times were longer for Witepsol\u00ae H15-based suppositories.", "population_specificity": "Not specified (study focused on formulation properties, not human subjects).", "effective_dosage": "Not specified (study used standardized Cannabis extractum normatum (CEX) without detailing CBD-specific dosages).", "study_duration": "24 months (stability study).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:09:07.080115+00:00"}
{"study_id": 5912, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the effectiveness of highly purified CBD for treating drug-resistant epilepsy (DRE) in adult patients through a systematic review and meta-analysis.", "results_summary": "The study found a statistically significant reduction in seizures among adult patients with DRE receiving CBD therapy compared to placebo, with moderate certainty of evidence according to GRADE and OCEBM level 2. Further prospective multicenter studies are recommended to confirm efficacy and safety.", "population_specificity": "Adult people with epilepsy (PWE) who have drug-resistant epilepsy (DRE).", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "CBD was used concomitantly with antiseizure medications in all studies.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:09:07.235297+00:00"}
{"study_id": 5915, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to assess the analgesic efficacy of CBD alone and in combination with meloxicam for pain management in female dogs undergoing ovariohysterectomy.", "results_summary": "CBD, alone or combined with meloxicam, showed comparable analgesic efficacy, controlling nociceptive cardiorespiratory and hemodynamic responses without significant differences between treatment groups. Facial thermal responses and physiological parameters indicated effective pain management in treated groups compared to placebo.", "population_specificity": "Female dogs of different breeds undergoing elective ovariohysterectomy.", "effective_dosage": "2 mg kg-1 orally every 12 h.", "study_duration": "48 hours postoperatively.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:09:08.800925+00:00"}
{"study_id": 5908, "supplement_id": 977, "safety_score": "70", "efficacy_score": 80, "quality_score": 65, "study_goal": "The researchers aimed to evaluate the clinical outcomes and safety of highly purified CBD (Epidyolex\u00ae) in pediatric patients with Lennox-Gastaut syndrome (LGS) or Dravet syndrome (DS) over 12 months.", "results_summary": "The study found a median reduction in motor seizures of 56.7% at 6 months and 60.0% at 12 months, with 65% and 67% of patients achieving \u226550% reduction, respectively. Adverse events, primarily gastrointestinal, were reported in 70% and 53% of patients at 6 and 12 months, respectively.", "population_specificity": "Pediatric patients aged 2-17 years with LGS (n=17) or DS (n=9).", "effective_dosage": "Median dosage was 6.0 mg/kg/day at 6 months and 7.3 mg/kg/day at 12 months.", "study_duration": "12 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:09:09.760417+00:00"}
{"study_id": 5918, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to investigate the effects of CBD on human cholangiocarcinoma (CCA) cells and the underlying mechanisms in vitro and in vivo.", "results_summary": "CBD inhibited CCA cell proliferation, suppressed colony formation, induced G0/G1 phase cell cycle arrest, and disrupted mitochondrial homeostasis. It also induced autophagy and cellular senescence via the PI3K/AKT/mTOR pathway.", "population_specificity": "Human CCA cell lines (KKU-213B, KKU-100, KKU-055) and a xenograft model.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:09:15.319907+00:00"}
{"study_id": 5917, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the effects of chronic CBD treatment on neuroinflammation, cannabinoid signaling, estrogen receptors, and microRNAs in male and female rats subjected to a depression model (UCMS).", "results_summary": "CBD reversed sex-specific behavioral effects of UCMS, normalized TNF-\u03b1 upregulation in males, restored CB1 and estrogen receptor gene expression in males, but had no effect on NF-\u03baB1 upregulation or miR-146a-5p alterations.", "population_specificity": "Male and female rats subjected to the unpredictable chronic mild stress (UCMS) model.", "effective_dosage": "Not specified", "study_duration": "Chronic (duration not specified)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:09:15.467109+00:00"}
{"study_id": 5916, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to investigate the molecular effects of low-dose CBD on U87MG glioma cells, focusing on its impact on cell viability, mitochondrial dynamics, autophagic flux, and redox systems.", "results_summary": "Low-dose CBD reduced U87MG glioma cell viability by 20% by altering mitochondrial membrane potential, increasing autophagic flux, and inducing pro-apoptotic proteins without activating Caspase-3 or Caspase-7. CBD also modulated redox systems and mitochondrial functionality, making cells more vulnerable to cytotoxic effects.", "population_specificity": "U87MG glioma cells (in vitro study)", "effective_dosage": "1 \u03bcM CBD", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:09:15.554358+00:00"}
{"study_id": 5920, "supplement_id": 977, "safety_score": "75", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the in vitro and in vivo effects of full-spectrum CBD oil on dystrophic muscle fibers in mdx mice, a model for Duchenne muscular dystrophy (DMD).", "results_summary": "In vitro, CBD showed dose-dependent cytotoxicity, but in vivo, 10 mg/kg/day improved multiple histopathological parameters (e.g., reduced central nuclei, inflammation, fibrosis) and lowered serum creatine kinase levels in mdx mice.", "population_specificity": "Mdx mice (a DMD model).", "effective_dosage": "10 mg/kg/day.", "study_duration": "14 days.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:09:16.187316+00:00"}
{"study_id": 5919, "supplement_id": 977, "safety_score": "85", "efficacy_score": 30, "quality_score": 75, "study_goal": "The researchers aimed to determine whether oral CBD affects interference during learning and memory (L&M) in healthy adults.", "results_summary": "CBD administration did not significantly impair L&M compared to placebo, but age might influence CBD's modulation of proactive interference during L&M. No effects were observed based on THC history, CBD use history, or sex.", "population_specificity": "35 healthy adults from the initial 57 enrolled volunteers.", "effective_dosage": "246 mg oral CBD.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:09:16.537452+00:00"}
{"study_id": 5921, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to review CBD's polypharmacological profile and evaluate its efficacy in neuropsychiatric disorders based on preclinical and clinical findings.", "results_summary": "The study highlights CBD's multifaceted mechanisms of action, suggesting neuroprotective, anti-inflammatory, anxiolytic, and antipsychotic effects, with potential benefits for neuropsychiatric disorders. Clinical trials are exploring its therapeutic uses beyond current approvals.", "population_specificity": "Not specified (review of preclinical and clinical research)", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:09:16.595403+00:00"}
{"study_id": 5922, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to determine whether CBD, along with other cannabinoids, could inhibit Nav1.8 channels and potentially serve as an analgesic for pain treatment.", "results_summary": "The study found that CBD effectively inhibits Nav1.8, suggesting its potential as an analgesic compound. However, CBG showed more significant promise in inhibiting peripheral sensory neuron excitability.", "population_specificity": "Not specified (likely preclinical or in vitro study based on abstract).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:09:17.652399+00:00"}
{"study_id": 5923, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 60, "study_goal": "The researchers aimed to investigate orthopedic sports medicine patients' perspectives on using THC- and CBD-based products for managing musculoskeletal pain.", "results_summary": "Most patients were familiar with CBD products (63.2%) and were more amenable to using CBD (90.1%) than THC (81.3%) for pain management. A majority (85.3%) believed cannabis-based products could help combat the opioid epidemic.", "population_specificity": "Orthopedic sports medicine patients", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:09:23.018339+00:00"}
{"study_id": 5927, "supplement_id": 977, "safety_score": "70", "efficacy_score": 60, "quality_score": 75, "study_goal": "The researchers aimed to investigate the functional and molecular effects of CBD on hippocampal slices, comparing its impact to THC, particularly in immature and mature brain tissue.", "results_summary": "CBD increased the expression of the post-synaptic protein PSD95 in immature hippocampal slices but did not affect pre-synaptic proteins. Unlike THC, CBD did not impair membrane properties, intrinsic excitability, or cause tissue disorganization, though it did impair mitochondrial function similarly to THC.", "population_specificity": "Rat organotypic hippocampal slices (immature and mature)", "effective_dosage": "1 \u00b5M", "study_duration": "7 days", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:09:24.346991+00:00"}
{"study_id": 5924, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to evaluate whether cannabidiol (CBD) could mitigate the toxic effects of cadmium exposure, particularly on oxidative stress, inflammation, and organ damage.", "results_summary": "CBD reduced oxidative stress markers (glutathione, catalase, myeloperoxidase) and proinflammatory cytokines (TNF-\u03b1, IL-1\u03b2, IL-6) in cadmium-exposed mice, protecting liver and kidney tissues but not testicular tissue.", "population_specificity": "Mice exposed to cadmium (50 mg/L in drinking water)", "effective_dosage": "25 mg/kg daily via intragastric gavage", "study_duration": "30 days", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:09:24.396998+00:00"}
{"study_id": 5925, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to investigate the metabolic changes in lipid patterns of acute and chronic myeloid leukemia cells after CBD treatment and assess its antiproliferative effects.", "results_summary": "CBD reduced cell viability and induced apoptosis and necrosis in both acute (HL-60) and chronic (K-562) myeloid leukemia cells, with HL-60 cells showing greater sensitivity. Lipidomic analysis revealed significant alterations in phospholipids and triacylglycerols, suggesting metabolic mechanisms linked to cell death.", "population_specificity": "Acute (HL-60) and chronic (K-562) myeloid leukemia cell lines.", "effective_dosage": "10 \u03bcM for HL-60 cells and 23 \u03bcM for K-562 cells.", "study_duration": "48 hours.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:09:25.003580+00:00"}
{"study_id": 5928, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to investigate the effect of a novel lipid formulation on the absorption of CBD in humans and its tissue distribution in mice.", "results_summary": "The lipid formulation significantly increased CBD plasma exposure (AUC0-48) by nine times compared to the powder formulation in humans. In mice, the lipid formulation resulted in measurable CBD concentrations in all organs, while the aqueous formulation showed no detectable levels.", "population_specificity": "Healthy fasting volunteers (human study) and male CD1 mice (animal study).", "effective_dosage": "1000 mg CBD (single dose in humans).", "study_duration": "Single-dose administration (humans); timepoints not specified (mice).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:09:25.421791+00:00"}
{"study_id": 5926, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to describe the population pharmacokinetics of CBD in children with drug-resistant developmental and epileptic encephalopathies (DEEs) and assess the influence of environmental, pharmacological, and clinical characteristics on CBD systemic exposure.", "results_summary": "The study found that CBD exposure increased by 41% in Cmax and 45% in AUC0-12 when administered with food compared to fasting, and dose-normalized AUC0-12 was approximately 50% lower with CBD-enriched oil compared to purified CBD.", "population_specificity": "Children aged 2-18 years with drug-resistant developmental and epileptic encephalopathies (DEEs).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "Food intake significantly increased CBD exposure, and formulation type (purified CBD vs. CBD-enriched oil) affected bioavailability.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:09:26.069703+00:00"}
{"study_id": 5929, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the potential synergy between Bixa orellana formulations and CBD-rich Cannabis sativa extract in reducing pain in experimental models.", "results_summary": "The study found that combining Bixa orellana formulations with CBD-rich Cannabis sativa extract significantly reduced pain in experimental tests, with superior effects compared to isolated use of either extract. The results suggest a synergistic action between the two plant extracts for pain reduction.", "population_specificity": "Wistar rats", "effective_dosage": "CSE (40 mg/kg, orally); CHR OR (400 mg/kg, orally); CHR IN (10 mg/kg, intramuscularly)", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:09:27.084948+00:00"}
{"study_id": 5930, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to investigate the effects of Cannabichromene (CBC) on Th2 cytokines and JAK/STAT pathways in a mouse model of atopic dermatitis (AD).", "results_summary": "CBC significantly reduced skin lesion severity, ear thickness, epithelial thickness, and mast cell infiltration, while also decreasing mRNA expression of Th2 cytokines and inflammatory mediators, as well as JAK/STAT protein expression.", "population_specificity": "BALB/c mice with DNCB-induced atopic dermatitis.", "effective_dosage": "0.1 mg/kg or 1 mg/kg, topically administered.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:09:32.057537+00:00"}
{"study_id": 5931, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to investigate the effect of long-term CBD treatment on renal transcriptome changes in a mouse model, focusing on gene expression related to circadian rhythm, glucocorticoid receptor function, lipid metabolism, and inflammatory response.", "results_summary": "CBD treatment altered gene expression in the kidneys, affecting genes linked to circadian rhythm, glucocorticoid receptor function, lipid metabolism, and inflammatory response, suggesting potential therapeutic benefits for kidney disease.", "population_specificity": "Male C57BL/6J mice", "effective_dosage": "10 mg/kg or 20 mg/kg body weight, daily intraperitoneal injections", "study_duration": "28 days", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:09:32.793197+00:00"}
{"study_id": 5932, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 70, "study_goal": "The researchers aimed to review the potential of CBD in managing pelvic floor pain disorders by examining its effects on muscle relaxation, pain relief, and inflammation reduction via the endocannabinoid system.", "results_summary": "The study suggests CBD may help relieve hyperalgesia and allodynia in pelvic floor disorders and promote muscle relaxation, but evidence supporting its efficacy and safety remains limited, and its mechanism of action is not fully understood.", "population_specificity": "Female population with painful pelvic floor disorders.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:09:32.930519+00:00"}
{"study_id": 5935, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to evaluate the quality of online information about CBD's potential effects on weight management, comparing Italian and English sources.", "results_summary": "The study found that online information about CBD and weight management was generally of low quality, with English sites being more trustworthy and neutral compared to Italian sites, which were predominantly commercial and promotional.", "population_specificity": "Online information consumers (Italian and English webpages)", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:09:33.912597+00:00"}
{"study_id": 5934, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 78, "study_goal": "The researchers aimed to determine whether CBD could modulate 5-HT2A receptor signaling, potentially reducing hallucinogenic effects associated with psychedelic compounds like LSD.", "results_summary": "CBD antagonized LSD-mediated Gq activation in a saturable manner without affecting \u03b2-arrestin2 recruitment, suggesting it acts as a negative allosteric modulator of 5-HT2A. SILCS simulations predicted CBD's binding site overlaps with oleamide, a positive allosteric modulator, potentially displacing orthosteric ligands.", "population_specificity": "HEK 293T cells and rat primary cortical neurons.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:09:34.206862+00:00"}
{"study_id": 50466, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 65, "study_goal": "The researchers aimed to evaluate the neuroprotective potential of CBD, focusing on its anti-inflammatory properties and therapeutic benefits for neurodegenerative diseases.", "results_summary": "The study found that CBD exhibits neuroprotective effects primarily through its anti-inflammatory activity, suggesting potential therapeutic benefits for neurodegenerative diseases, though limitations as a candidate for neuroprotective therapies were noted.", "population_specificity": "Not specified (general focus on neurodegenerative diseases)", "effective_dosage": "Not provided", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:09:34.365631+00:00"}
{"study_id": 5933, "supplement_id": 977, "safety_score": "45", "efficacy_score": 60, "quality_score": 75, "study_goal": "The researchers aimed to compare the effects of gestational exposure to high-CBD Cannabis smoke versus injected CBD on offspring health and behavior.", "results_summary": "GCE to high-CBD smoke had less severe impacts on maternal and litter health compared to injected CBD. Injected CBD impaired prepulse inhibition in adult offspring and increased social proximity time in males.", "population_specificity": "Pregnant dams and their offspring (preclinical animal model).", "effective_dosage": "Not specified", "study_duration": "Gestational period (exact duration not specified)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:09:35.533451+00:00"}
{"study_id": 50471, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 20, "quality_score": 65, "study_goal": "The researchers aimed to critically evaluate the existing literature on CBD's pharmacology and clinical effects to address inconsistencies and contradictions in reported findings.", "results_summary": "The study found that many of CBD's purported effects may be false positives or artifacts unlikely to occur under physiological conditions, with limited demonstrable clinical benefits or notable side effects.", "population_specificity": "Not specified (literature review)", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:09:40.103118+00:00"}
{"study_id": 50470, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to determine whether a single dose of CBD could reduce alcohol craving and nucleus accumbens activation in individuals with alcohol use disorder (AUD).", "results_summary": "Individuals receiving CBD showed lower bilateral cue-induced nucleus accumbens activation and reduced alcohol craving during stress- and alcohol cue exposure compared to placebo.", "population_specificity": "28 individuals with alcohol use disorder (AUD).", "effective_dosage": "800 mg (single dose).", "study_duration": "Single administration.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:09:40.238388+00:00"}
{"study_id": 50473, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to analyze the effects of CBD on somatic stem cells (SSCs) and cancer stem cells (CSCs), focusing on differentiation, protective activity, and antiproliferative effects.", "results_summary": "CBD showed differentiating and protective effects on SSCs and demonstrated antiproliferative effects on some CSCs, though most analyses were conducted in vitro. Clinical justification would require further in vivo studies.", "population_specificity": "Somatic stem cells (SSCs) and cancer stem cells (CSCs), including glioblastoma, lung cancer, and breast cancer.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:09:43.479091+00:00"}
{"study_id": 50469, "supplement_id": 977, "safety_score": "90", "efficacy_score": 70, "quality_score": 85, "study_goal": "The researchers aimed to determine whether a single 400-mg oral dose of FDA-approved CBD improves clinical anxiety in women with advanced breast cancer.", "results_summary": "The study found no significant difference in the primary endpoint (change in anxiety scores pre- and post-ingestion between CBD and placebo arms), but anxiety levels were significantly lower in the CBD group 2-4 hours after ingestion. No grade 3 or 4 toxic effects were reported, suggesting CBD is safe for this population.", "population_specificity": "Women aged 18+ with advanced breast cancer and baseline clinical anxiety.", "effective_dosage": "Single 400-mg oral dose.", "study_duration": "Single administration, effects measured 2-4 hours post-ingestion.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:09:44.403092+00:00"}
{"study_id": 50476, "supplement_id": 977, "safety_score": "75", "efficacy_score": 80, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the efficacy, safety, and non-seizure outcomes of Cannabidiol (CBD) as an antiseizure medication for Dravet syndrome.", "results_summary": "The study found that CBD demonstrated efficacy in reducing seizures in Dravet syndrome patients, with sustained safety and potential improvements in non-seizure outcomes like cognitive development and quality of life. However, long-term seizure control remained suboptimal.", "population_specificity": "Patients with Dravet syndrome, a severe genetic developmental and epileptic encephalopathy.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:09:45.496835+00:00"}
{"study_id": 50479, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The researchers were exploring the potential of phytocannabinoids, including CBD, as an alternative therapy for Autism Spectrum Disorder (ASD).", "results_summary": "The abstract does not provide specific findings regarding CBD's effects on ASD.", "population_specificity": "Individuals with Autism Spectrum Disorder (ASD).", "effective_dosage": "Not available", "study_duration": "Not available", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:09:46.562457+00:00"}
{"study_id": 50474, "supplement_id": 977, "safety_score": "75", "efficacy_score": 70, "quality_score": 80, "study_goal": "The researchers aimed to investigate the effects of short-term repeated use of 60 mg CBD on liver activity during high-intensity exercise and assess potential hepatotoxic effects.", "results_summary": "The study found that 60 mg CBD reduced exercise-induced increases in liver enzymes (GOT and GPT) in advanced athletes but not in highly advanced athletes. No evidence of hepatotoxicity was observed at this dosage over seven days, though pharmacological effects on the liver were noted.", "population_specificity": "Seventeen well-trained, healthy athletes (26\u00b14 years, 181\u00b15 cm, 85.6\u00b19.4 kg) divided into advanced and highly advanced performance levels.", "effective_dosage": "60 mg CBD per day (oil and solubilisate forms).", "study_duration": "7 days.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:09:47.250898+00:00"}
{"study_id": 50480, "supplement_id": 977, "safety_score": "80", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to explore the pharmacological properties, mechanisms of action, and clinical evidence supporting CBD's use in pediatric epilepsies, as well as the regulatory landscape in India.", "results_summary": "The study found that CBD reduces seizure frequency and improves quality of life in children with drug-resistant epilepsy, with a generally favorable safety profile and minor adverse effects like somnolence and diarrhea. However, cost remains a significant barrier, especially in low- and middle-income countries.", "population_specificity": "Children with drug-resistant epilepsy, specifically Dravet syndrome, Lennox Gastaut syndrome, and Tuberous sclerosis complex.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:09:50.190364+00:00"}
{"study_id": 50481, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to review the potential of CBD-containing formulations for treating endometriosis-related pain and fatigue, summarizing existing data on pathophysiology, pharmacokinetics, and ongoing clinical trials.", "results_summary": "The abstract summarizes data suggesting CBD's activity in pathways relevant to endometriosis and notes ongoing clinical trials, but does not provide specific efficacy results. It highlights interest in CBD for endometriosis but lacks conclusive findings.", "population_specificity": "Patients with endometriosis and animal models of the condition.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:09:51.711420+00:00"}
{"study_id": 50482, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the therapeutic potential of minor cannabinoids, including Cannabidiol (CBD), in psychiatric disorders through a systematic review of preclinical and clinical studies.", "results_summary": "The abstract does not specifically report findings on CBD's effects, focusing instead on minor cannabinoids like \u03948-THCV, \u03949-THCV, CBDA-ME, and CBDV for various psychiatric conditions.", "population_specificity": "Preclinical studies (animal models) and one clinical study (human participants) investigating psychiatric disorders.", "effective_dosage": "Not specified for CBD.", "study_duration": "Not specified for CBD.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:09:53.174027+00:00"}
{"study_id": 50484, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 20, "quality_score": 65, "study_goal": "The researchers aimed to evaluate the effectiveness of CBD-rich Cannabis extract in reducing anxiety and postoperative pain in patients undergoing endodontic treatment.", "results_summary": "The study found no significant difference in anxiety reduction or postoperative pain between the CBD and placebo groups at any measured time point. Mean anxiety scores were higher in the CBD group than the placebo group, but the difference was not statistically significant.", "population_specificity": "Patients submitted to endodontic treatment.", "effective_dosage": "Not specified", "study_duration": "Assessments were made before treatment and at 24, 48, 72 hours, and 7 days post-treatment.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:09:53.992416+00:00"}
{"study_id": 50489, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the potential of Cannabidiol (CBD) as a therapeutic approach for major depressive disorder by examining its pharmacological effects and contrasting them with the pathological mechanisms of the disease.", "results_summary": "The study highlights CBD's potential in treating major depressive disorder, citing its analgesic, anti-inflammatory, antineoplastic, and neuroprotective roles observed in animal models and clinical trials. However, it contrasts current evidence of CBD's administration and pharmacology against the pathological mechanisms of depression without definitive conclusions.", "population_specificity": "Major depressive disorder patients (implied, not explicitly stated).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:09:56.142980+00:00"}
{"study_id": 50487, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 65, "study_goal": "The researchers aimed to explore the potential of CBD, THC, and other trace cannabinoids in treating CDKL5 Deficiency Disorder (CDD), focusing on clinical trials and preclinical models to understand their mechanisms of action.", "results_summary": "The abstract highlights CBD's promise in treating drug-resistant genetic epilepsies like Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), and Tuberous Sclerosis Complex (TSC), but notes limited specific research on CDD, with much evidence relying on anecdotal reports of artisanal products.", "population_specificity": "Pediatric patients with genetic epilepsies, particularly CDKL5 Deficiency Disorder (CDD).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:09:56.437580+00:00"}
{"study_id": 50490, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 65, "study_goal": "The researchers aimed to evaluate the current evidence on the use of CBD for cosmetic purposes, focusing on its pharmacological properties and potential benefits in dermatology.", "results_summary": "The study found that CBD exhibits anti-oxidant, anti-inflammatory, moisturizing, anti-acne, wound-healing, and anti-aging properties based on in vitro and in vivo evidence, but clinical studies are limited. There is also a need for improved drug-delivery systems for topical/transdermal CBD application.", "population_specificity": "Not specified (general dermatological/cosmetic applications)", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:09:57.110343+00:00"}
{"study_id": 50491, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to determine the safety, tolerability, and dosing of a CBD-enriched Cannabis Herbal Extract (CHE) for treating chronic headaches in adolescents.", "results_summary": "The study protocol describes an open-label, dose-escalation trial but does not report results on safety, efficacy, or outcomes, as it appears to be a preliminary or ongoing study.", "population_specificity": "Adolescents aged 14-17 years with chronic migraine unresponsive to other therapies.", "effective_dosage": "Starting at 0.2-0.4 mg/kg of CBD per day, escalating monthly up to 0.8-1.0 mg/kg of CBD per day.", "study_duration": "Monthly dose escalation (exact total duration not specified).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:10:00.075713+00:00"}
{"study_id": 50493, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 50, "study_goal": "The researchers aimed to raise awareness of potential medication interactions involving CBD in dermatologic therapy.", "results_summary": "The study highlighted CBD's mechanism and potential interactions with medications for dermatologic conditions but did not report specific efficacy outcomes.", "population_specificity": "Patients with dermatologic conditions (acne, allergic contact dermatitis, atopic dermatitis, pruritus, skin aging, skin cancer, psoriasis).", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "Potential interactions with medications for dermatologic conditions mentioned, but specifics not detailed.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:10:00.663331+00:00"}
{"study_id": 50492, "supplement_id": 977, "safety_score": "80", "efficacy_score": 70, "quality_score": 60, "study_goal": "The researchers aimed to summarize the evidence on the effectiveness and safety of medicinal cannabis, including Cannabidiol (CBD), particularly for conditions like refractory epilepsy.", "results_summary": "The study found that CBD may produce small to modest benefits in treating refractory epilepsy, but evidence on its efficacy for other conditions remains inconclusive. Cannabis-based medicine, including CBD, is generally well tolerated but carries a risk of mild to moderate adverse effects and cannabis use disorder (CUD).", "population_specificity": "Not specified (general medical and recreational cannabis users, with some focus on adolescents and young adults for adverse outcomes).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:10:00.955532+00:00"}
{"study_id": 50494, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 70, "study_goal": "The researchers aimed to explore the potential of cannabidiol (CBD) in pain management, particularly its role in modulating pain through epigenetic mechanisms involving opioid and cannabinoid receptors.", "results_summary": "The abstract suggests that CBD, as a non-psychoactive cannabinoid, may offer new clinical perspectives in pain management by preserving the activity of opioid and endocannabinoid systems, potentially enhancing analgesic efficacy. However, specific results or outcomes related to CBD's effectiveness are not detailed.", "population_specificity": "Not specified in the abstract.", "effective_dosage": "Not mentioned.", "study_duration": "Not mentioned.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:10:02.603008+00:00"}
{"study_id": 50496, "supplement_id": 977, "safety_score": "30", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the association between CBD use and liver enzyme elevations/drug-induced liver injury (DILI) and provide clinical guidance for managing CBD-related hepatotoxicity.", "results_summary": "The study found that CBD use is associated with clinically significant liver enzyme elevations and DILI, meeting the criteria for a common adverse drug reaction. It highlights the need for clinical guidance in diagnosing and managing CBD-associated hepatotoxicity.", "population_specificity": "Not specified (general CBD users, both medical and non-medical).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:10:04.425506+00:00"}
{"study_id": 50472, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 80, "study_goal": "The researchers aimed to analyze the effects of CBD on male reproductive health, comparing its potential benefits to the negative effects of THC.", "results_summary": "The study suggests CBD may have protective and beneficial effects on male reproductive health, potentially due to its anti-inflammatory and antioxidant properties, in contrast to THC's negative impacts.", "population_specificity": "Male reproductive health (specific population details not provided).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:10:06.521439+00:00"}
{"study_id": 50495, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to determine an optimal CBD dose based on pharmacokinetic, physiological, and psychological data in contact-sport athletes to assess its potential in reducing mild traumatic injuries and enhancing recovery.", "results_summary": "The study is ongoing, so no results are reported yet; it focuses on developing a dosing regimen and correlating physiological and psychological effects with pharmacokinetic data.", "population_specificity": "Healthy, male university athletes involved in contact sports.", "effective_dosage": "Escalating doses from 5 mg CBD/kg/day to 30 mg CBD/kg/day, increased every two weeks in 5 mg increments.", "study_duration": "10 visits (exact duration not specified, but dose escalation occurs every two weeks).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:10:06.653294+00:00"}
{"study_id": 50498, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to assess the effects of CBD on endocannabinoid levels (AEA, OEA, PEA) and compare its impact with other phytocannabinoids in a clinical setting, particularly in relation to schizophrenia treatment.", "results_summary": "CBD administration led to significant increases in AEA (1.6-fold), OEA, and PEA (1.4-fold) at an 800 mg dose, suggesting potential clinical benefits for acute schizophrenia. The effects were dose-dependent, with higher doses showing more pronounced outcomes.", "population_specificity": "Patients in clinical trials, likely with schizophrenia (implied but not explicitly stated).", "effective_dosage": "600 mg or 800 mg single oral dose.", "study_duration": "Single-dose intervention (duration not specified beyond this).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:10:07.319972+00:00"}
{"study_id": 50499, "supplement_id": 977, "safety_score": "40", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to explore the risk and frequency of adverse events (AEs) in epilepsy patients treated with CBD.", "results_summary": "CBD use in epileptic patients was linked to a 10.87% seizure-free rate but also an increased risk of ample adverse events. Further research is needed to understand CBD's effectiveness and side effects across different epilepsy forms.", "population_specificity": "Epilepsy patients", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:10:07.450608+00:00"}
{"study_id": 50501, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 65, "study_goal": "The researchers aimed to explore the potential of CBD as a treatment for endometriosis by targeting inflammation and angiogenesis pathways.", "results_summary": "The study found that CBD has anti-inflammatory and antiangiogenic properties, reducing key cytokines (IL-1\u03b2, IL-6, TNF-\u03b1) and angiogenic factors (VEGF, TGF\u03b2, MMPs) in animal models, suggesting potential efficacy for endometriosis treatment.", "population_specificity": "Animal models (specific species not mentioned).", "effective_dosage": "Not specified.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:10:09.090510+00:00"}
{"study_id": 50500, "supplement_id": 977, "safety_score": "80", "efficacy_score": 70, "quality_score": 85, "study_goal": "The researchers aimed to determine the effects of daily CBD use on neurocognitive performance and subjective mood in individuals with primary insomnia.", "results_summary": "Cognitive performance was unaffected by nightly CBD use, but participants reported increased calmness, clear-headedness, and coordination, along with side effects like dry mouth. The study concluded that CBD preserved daytime cognitive functioning and had a favorable safety profile.", "population_specificity": "Individuals with primary insomnia (N=30, 15 in CBD group, 15 in placebo group).", "effective_dosage": "150 mg CBD sublingually, daily before bed.", "study_duration": "2 weeks of dosing following a 1-week placebo run-in.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:10:09.642696+00:00"}
{"study_id": 50502, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 70, "study_goal": "The researchers aimed to evaluate the benefits of CBD, among other therapies, for treating drug-resistant epilepsy in patients with KCNT1-related epilepsies.", "results_summary": "CBD showed benefit in 50% of EIMFS patients (6/12) and 1 out of 2 DEE patients, indicating moderate efficacy in reducing seizures or improving quality of life. The study did not provide detailed statistical analysis or effect sizes for CBD's outcomes.", "population_specificity": "Patients with KCNT1-related epilepsies, specifically EIMFS, (AD)SHE, and DEE phenotypes.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:10:11.263678+00:00"}
{"study_id": 50506, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The researchers aimed to explore the potential of cannabidiol (CBD) as a targeting strategy for pain relief through the endocannabinoid signaling system.", "results_summary": "The abstract does not provide specific findings on CBD's effects, only mentioning it as a focus of the review.", "population_specificity": "Not specified", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:10:14.221732+00:00"}
{"study_id": 50505, "supplement_id": 977, "safety_score": "80", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to critically analyze the potential role of CBD as an adjunctive therapy in schizophrenia treatment, focusing on its antipsychotic, anxiolytic, and neuroprotective effects.", "results_summary": "CBD demonstrated efficacy in reducing both positive and negative symptoms of schizophrenia, with a lower incidence of side effects and favorable tolerability compared to traditional antipsychotics. Its therapeutic action may involve receptor activation and suppression, along with anti-inflammatory and antioxidative effects.", "population_specificity": "Patients with schizophrenia", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:10:14.597706+00:00"}
{"study_id": 50504, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 65, "study_goal": "The researchers aimed to explore the potential of Cannabidiol (CBD) to synergize with photodynamic therapy (PDT) for improving the treatment efficacy of malignant melanoma (MM).", "results_summary": "The study suggests that CBD may enhance the efficacy of anticancer agents like PDT, but its low bioavailability due to poor water compatibility, absorption, and rapid metabolism limits its effectiveness. Nanotechnology is proposed as a solution to improve CBD's biological efficiency and targeted specificity.", "population_specificity": "Malignant melanoma (MM) tumors (in vitro or in vivo context not specified).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:10:14.995413+00:00"}
{"study_id": 50509, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 65, "study_goal": "The researchers aimed to review the potential of CBD for treating substance use disorders (SUD), focusing on its therapeutic applications and molecular mechanisms.", "results_summary": "The abstract suggests CBD shows promise for treating SUD, particularly for cocaine and psychostimulant drugs, though studies are limited compared to other conditions like epilepsy.", "population_specificity": "Individuals with substance use disorders (SUD), particularly related to cocaine and psychostimulants.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:10:15.003686+00:00"}
{"study_id": 50503, "supplement_id": 977, "safety_score": "75", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the long-term efficacy and safety of add-on CBD treatment in patients with tuberous sclerosis complex (TSC) and treatment-resistant epilepsy.", "results_summary": "Long-term CBD use was associated with significant reductions in seizure frequency (44%-87% across seizure types) and responder rates (46%-79% for \u226550% reduction). Safety results were consistent with prior studies, with common side effects including somnolence, diarrhea, and ataxia.", "population_specificity": "Patients with tuberous sclerosis complex (TSC) and treatment-resistant epilepsy (mean age 12.4 years, range 1.8-31.2).", "effective_dosage": "Median dose of 25-28 mg/kg/d for 36 weeks, then 20-50 mg/kg/d through 228 weeks.", "study_duration": "Up to 228 weeks (approximately 4.4 years).", "interactions": "Dose reduction occurred for most antiseizure medications (ASMs) except topiramate.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:10:16.492306+00:00"}
{"study_id": 50511, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 70, "study_goal": "The researchers aimed to explore the potential of Cannabidiol (CBD) as an alternative treatment for chronic pain, focusing on its safety, efficacy, and mechanisms of action.", "results_summary": "The study suggests CBD shows promise in managing chronic pain, particularly for cancer-related, neuropathic, arthritis, and musculoskeletal pain, based on animal studies and preliminary evidence, though human efficacy remains contentious.", "population_specificity": "Adults with chronic pain (specific population not detailed).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:10:17.109279+00:00"}
{"study_id": 50512, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to explore CBD's effects, molecular mechanisms, and potential as a treatment for Major Depressive Disorder (MDD).", "results_summary": "The abstract suggests CBD shows promising results in preclinical models and human studies, potentially involving monoamine and endocannabinoid signaling, neuroinflammation control, and enhanced neuroplasticity. However, its mechanism is not well-understood, and traditional treatments remain partially effective.", "population_specificity": "Not specified (abstract mentions preclinical models and human studies broadly).", "effective_dosage": "Not provided", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:10:18.389507+00:00"}
{"study_id": 50513, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to review the history and current evidence of CBD's anxiolytic effects and explore its potential clinical use in anxiety disorders.", "results_summary": "The study highlights compelling evidence supporting CBD's anxiolytic effects, suggesting therapeutic potential for anxiety disorders, though it does not provide specific quantitative outcomes.", "population_specificity": "Patients with anxiety disorders (general, not further specified).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:10:18.799900+00:00"}
{"study_id": 50515, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 65, "study_goal": "The researchers aimed to overview the pharmacology of CBD and its potential mechanisms of action as an antiseizure drug (ASD) for treating epileptic syndromes.", "results_summary": "The study found that CBD has reached clinical use for certain epileptic syndromes, with its antiseizure effects likely involving multiple neurotransmitters, receptors, and intracellular pathways. However, limitations and future research perspectives were noted.", "population_specificity": "Patients with certain epileptic syndromes (specific population not detailed in abstract).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:10:22.354222+00:00"}
{"study_id": 50514, "supplement_id": 977, "safety_score": "85", "efficacy_score": 70, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the potential therapeutic effects of CBD on Autism Spectrum Disorder (ASD) symptoms and comorbidities, focusing on its interaction with the endocannabinoid system and gut microbiota.", "results_summary": "Preliminary findings suggest CBD may modulate specific ASD symptoms and comorbidities, with emerging evidence indicating potential effects on gut microbiota. CBD is described as safe with low side effects and a multi-target pharmacological profile.", "population_specificity": "Individuals with Autism Spectrum Disorder (ASD).", "effective_dosage": "Not Assessed", "study_duration": "Not Assessed", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:10:22.810169+00:00"}
{"study_id": 50518, "supplement_id": 977, "safety_score": "80", "efficacy_score": 75, "quality_score": 70, "study_goal": "The researchers aimed to provide a historical overview of CBD's evolution from an \"inactive substance\" to a multifunctional clinical agent and discuss current challenges in researching its therapeutic potential.", "results_summary": "The abstract highlights that CBD does not produce psychotomimetic effects or induce dependence and is currently used as a medication for certain epileptic syndromes. Pre-clinical and clinical studies support its potential use in various other disorders, though challenges in research remain.", "population_specificity": "Not specified (general discussion of pre-clinical and clinical studies).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:10:25.533939+00:00"}
{"study_id": 50519, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to determine whether topically applied nano-CBD (nCBD) cream could mitigate UV-A-induced skin damage, including inflammation, oxidative stress, and DNA mutations.", "results_summary": "The study found that nCBD-treated skin showed reduced UV-A-induced epidermal hyperplasia, decreased mutagenic DNA base lesions, and protection against mitochondrial DNA mutations compared to vehicle control. Additionally, 21% of participants exhibited less erythema on CBD-treated skin.", "population_specificity": "19 participants (specific demographics not detailed in the abstract).", "effective_dosage": "Not specified (applied twice daily).", "study_duration": "14 days.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:10:25.608410+00:00"}
{"study_id": 50522, "supplement_id": 977, "safety_score": "30", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to assess the hepatotoxicity and transcriptional effects of CBD and other cannabinoids using human iPSC-derived hepatocytes.", "results_summary": "CBD impaired liver metabolism and caused oxidative stress in hepatocytes, with transcriptional potency ranking second among the tested cannabinoids (CBN > CBD > CBC > CBG). The study suggests potential hepatotoxic effects of CBD.", "population_specificity": "Human induced pluripotent stem cell (iPSC)-derived hepatocytes", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:10:27.459083+00:00"}
{"study_id": 50521, "supplement_id": 977, "safety_score": "75", "efficacy_score": 80, "quality_score": 85, "study_goal": "The researchers aimed to establish consensus recommendations for optimizing Epidiolex (CBD) treatment in patients with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex, focusing on dosing, safety, and differentiation from nonapproved CBD products.", "results_summary": "The study found that accurate patient identification, individualized dosing, and awareness of drug interactions are critical for optimizing Epidiolex treatment. Panelists emphasized managing adverse events and tracking response to the maximum tolerated dose as key measures of effectiveness.", "population_specificity": "Patients with Lennox-Gastaut syndrome, Dravet syndrome, and tuberous sclerosis complex.", "effective_dosage": "Initial target dose and titration rate individualized based on baseline variables, prior response to antiseizure medications, and therapeutic goals (specific amounts not provided).", "study_duration": "Not specified.", "interactions": "Drug-drug interactions mentioned as a critical consideration.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:10:28.815425+00:00"}
{"study_id": 50523, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to summarize preclinical and clinical research on CBD's potential in glioma therapy, including its anti-tumoral, anti-inflammatory, and neuroprotective properties.", "results_summary": "The review highlights CBD's promising anti-tumoral, anti-inflammatory, and neuroprotective effects in glioma therapy but also discusses potential challenges and the current status of nanomedicine formulations.", "population_specificity": "Glioma patients (preclinical and clinical research reviewed).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:10:30.575837+00:00"}
{"study_id": 50525, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to explore the molecular mechanisms and clinical applications of CBD in managing neurodegenerative disorders (NDs) and other neurological conditions.", "results_summary": "CBD demonstrated antioxidant, anti-inflammatory, and neuroprotective effects in various NDs, inhibiting protein aggregation, free radicals, and neuroinflammation. It also showed promise in treating epilepsy, depression, schizophrenia, and anxiety, both alone and as an adjuvant therapy.", "population_specificity": "Primarily focused on neurodegenerative disorders (e.g., Alzheimer's, Parkinson's) and other neurological conditions (e.g., epilepsy, depression).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:10:32.061575+00:00"}
{"study_id": 50526, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to determine whether an oral CBD solution improves chronic pain symptoms in Veterans, as measured by the Patient Global Impression of Change (PGIC), compared to placebo.", "results_summary": "The study is ongoing, so no results are available yet. Once completed, it will assess CBD's impact on pain severity, interference, anxiety, suicide ideation, and sleep disturbance.", "population_specificity": "Veterans with chronic pain", "effective_dosage": "Not specified", "study_duration": "4 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:10:32.981705+00:00"}
{"study_id": 50517, "supplement_id": 977, "safety_score": "75", "efficacy_score": 65, "quality_score": 80, "study_goal": "The researchers aimed to explore CBD's therapeutic potential in neurodegenerative and psychiatric disorders, its pharmacokinetic challenges, and the role of nanobiotechnology in improving its delivery.", "results_summary": "The study found CBD has potential therapeutic applications for conditions like schizophrenia, multiple sclerosis, and Alzheimer's, but faces challenges in bioavailability and dosing precision. Nanobiotechnology shows promise in enhancing CBD's stability and reducing toxicity.", "population_specificity": "Patients with neurodegenerative and psychiatric disorders (e.g., schizophrenia, multiple sclerosis, Alzheimer's, Parkinson's, stress-related disorders).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:10:34.846235+00:00"}
{"study_id": 50527, "supplement_id": 977, "safety_score": "85", "efficacy_score": 80, "quality_score": 90, "study_goal": "The researchers aimed to investigate CBD's impact on lipid responses triggered by second-generation antipsychotics (SGAs) and its potential to alleviate metabolic side effects.", "results_summary": "The study found that CBD restored sphingomyelin and ceramide levels altered by SGAs, potentially mitigating metabolic side effects like weight gain. CBD appeared to arrest or attenuate adverse lipid changes associated with olanzapine, quetiapine, and risperidone.", "population_specificity": "38 healthy volunteers", "effective_dosage": "800 mg/day (CBD)", "study_duration": "6 days (combined SGA and CBD treatment)", "interactions": "Second-generation antipsychotics (amisulpride, quetiapine, olanzapine, risperidone)", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:10:35.107856+00:00"}
{"study_id": 50516, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 60, "quality_score": 50, "study_goal": "The researchers aimed to evaluate the potential therapeutic benefits of CBD in mitigating cognitive decline and neurodegeneration in Alzheimer's disease (AD) models.", "results_summary": "Pre-clinical and in vitro studies suggest CBD may reduce cognitive decline and amyloid-beta-induced neurodegeneration by modulating oxidative stress and neuroinflammation, while also promoting neuroplasticity. However, clinical evidence is conflicting, and no randomized placebo-controlled trials have been conducted to confirm these effects.", "population_specificity": "Pre-clinical and in vitro models, with implications for Alzheimer's disease patients.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:10:35.165346+00:00"}
{"study_id": 50529, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 70, "study_goal": "The researchers aimed to evaluate the therapeutic potential of CBD in treating neuropsychiatric and anxiety disorders, focusing on its efficacy for GAD, SAD, and PTSD.", "results_summary": "The meta-analysis found a significant impact of CBD on anxiety, with a considerable effect size (Hedges' g = -0.92), though the authors caution interpretation due to limited sample size.", "population_specificity": "316 participants across eight studies, focusing on individuals with anxiety disorders (GAD, SAD, PTSD).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:10:35.566313+00:00"}
{"study_id": 50530, "supplement_id": 977, "safety_score": "40", "efficacy_score": null, "quality_score": 60, "study_goal": "The researchers aimed to review human-derived data on the toxicological effects and safety concerns associated with non-pharmaceutical CBD use.", "results_summary": "The study found that CBD use in humans is linked to adverse effects such as appetite changes, gastrointestinal discomfort, fatigue, and elevated liver enzymes. Animal studies also reported impacts on organ weight, reproduction, liver function, and the immune system.", "population_specificity": "Humans and animals (specific populations not detailed in the abstract).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:10:36.617697+00:00"}
{"study_id": 50532, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The researchers were exploring the potential of nanotechnology to enhance the therapeutic potential and stability of cannabidiol (CBD).", "results_summary": "The abstract does not provide specific findings on CBD's effects, only mentioning its potential in nanotechnology-based drug delivery systems.", "population_specificity": "Not specified", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:10:38.823872+00:00"}
{"study_id": 50531, "supplement_id": 977, "safety_score": "85", "efficacy_score": 70, "quality_score": 75, "study_goal": "The researchers aimed to assess the safety, tolerability, and potential effects of CBD on immune/inflammatory biomarkers and subjective measures like pain and vigor-activity in healthy adults.", "results_summary": "CBD was safe and well-tolerated, with lower reported pain in the CBD group. However, no significant changes were observed in immune or inflammatory biomarkers, and \"vigor-activity\" decreased, possibly due to academic semester effects.", "population_specificity": "54 healthy males and females (age 25 \u00b1 7 years; BMI 24.82 \u00b1 3.25 kg/m\u00b2).", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:10:39.237155+00:00"}
{"study_id": 50535, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to identify the clinical pharmacokinetic properties of CBD through meta-analysis and explore factors contributing to its variability.", "results_summary": "The study found that CBD pharmacokinetics are significantly influenced by diet, liver function, and formulation, with increased plasma exposure under certain conditions. CBD absorption was rapid across various exposure routes, and lipid emulsification/nanoformulation improved bioavailability.", "population_specificity": "Not specified (meta-analysis of clinical trial reports)", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "Diet (increased plasma exposure), THC (no antagonistic effect on absorption), liver function changes (significant impact on pharmacokinetics)", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:10:41.653333+00:00"}
{"study_id": 50536, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to summarize the structural activity relationship of CBD with different receptors and investigate its interaction mechanisms to optimize CBD-based therapies.", "results_summary": "The study highlighted CBD's diverse clinical properties, including anticancer, antiinflammatory, antidepressant, and antiepileptic effects, and explored its interaction with receptors to guide therapeutic applications.", "population_specificity": "Not specified (review of existing research).", "effective_dosage": "Not specified.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:10:41.765717+00:00"}
{"study_id": 50538, "supplement_id": 977, "safety_score": "90", "efficacy_score": 95, "quality_score": 85, "study_goal": "To evaluate the efficacy, safety, and pharmacokinetics of nanodispersible CBD oral solution versus placebo for treating mild to moderate anxiety disorders.", "results_summary": "Nanodispersible CBD significantly improved anxiety symptoms (GAD-7 and HAM-A scores) and secondary outcomes (depression and sleep quality) compared to placebo, with no serious adverse events reported. The treatment was well-tolerated and effective.", "population_specificity": "Individuals with mild to moderate anxiety disorders in India.", "effective_dosage": "Not specified", "study_duration": "15 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:10:44.123628+00:00"}
{"study_id": 50537, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 85, "study_goal": "The researchers aimed to determine whether CBD attenuates THC's effects on brain-network connectivity in adolescents and young adults.", "results_summary": "CBD did not counteract THC's effects and further reduced connectivity within brain networks and the whole brain. The study found no evidence that CBD makes cannabis safer, as it sometimes potentiated THC's disruptive effects.", "population_specificity": "Semi-regular cannabis users (0.5-3 days/week), including 22 adolescents (16-17 years) and 24 young adults (26-29 years).", "effective_dosage": "THC: 8 mg/75 kg; THC + CBD: 8 mg/75 kg THC & 24 mg/75 kg CBD.", "study_duration": "Single administration (acute effects measured via fMRI).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:10:44.209953+00:00"}
{"study_id": 50539, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 60, "study_goal": "The researchers aimed to explore the therapeutic potential of CBD in treating various oral diseases and summarize its pharmacological effects, receptor distribution, and possible administration routes.", "results_summary": "The study found that CBD has therapeutic potential for oral diseases such as periodontal diseases, pulp diseases, oral mucosal diseases, oral cancer, and temporomandibular joint diseases, but noted a lack of systematic research. It also summarized CBD's pharmacological effects and administration routes.", "population_specificity": "Not specified (general oral disease context)", "effective_dosage": "Not provided", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:10:44.992849+00:00"}
{"study_id": 50540, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 65, "study_goal": "The researchers aimed to assess the feasibility and effects of a transdermal CBD gel on pain, functionality, and quality of life in individuals with hand osteoarthritis.", "results_summary": "The study found significant reductions in pain, improvements in grip strength, and enhanced quality of life measures (fatigue, stiffness, anxiety) after four weeks of CBD gel application, though self-reported functionality did not improve. Pain and grip strength benefits reverted toward baseline after treatment cessation.", "population_specificity": "Individuals with symptomatically active hand osteoarthritis.", "effective_dosage": "4% w/w CBD gel applied three times daily.", "study_duration": "Four weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:10:45.920167+00:00"}
{"study_id": 50543, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to understand the mechanisms underlying CBD's antidepressant effects, focusing on serotonin and BDNF-TrkB signaling in the prefrontal cortex.", "results_summary": "The study suggests CBD's antidepressant effects involve serotonin release in the PFC and facilitation of BDNF-TrkB signaling, leading to rapid neuroplastic changes. These mechanisms may contribute to CBD's potential as an antidepressant.", "population_specificity": "Animal models (not specified further).", "effective_dosage": "Not specified.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:10:46.181865+00:00"}
{"study_id": 50545, "supplement_id": 977, "safety_score": "80", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to consolidate current knowledge on the efficacy, safety, pharmacology, and therapeutic mechanisms of CBD in treating epilepsy, particularly in children and adolescents with drug-resistant epilepsies (DREs).", "results_summary": "The meta-analyses confirmed CBD's effectiveness and safety in children and adolescents with DREs, though insufficient data prevented reliable conclusions for adults. The study highlighted variations in meta-analysis criteria but overall supported CBD's therapeutic use.", "population_specificity": "Children and adolescents (\u22652 years) with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), and tuberous sclerosis complex (TSC).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "Drug-drug interactions mentioned but not detailed", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:10:48.862027+00:00"}
{"study_id": 50546, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to review the proposed antitumor mechanisms of CBD to provide references for clinical treatment and rational use of CBD.", "results_summary": "The study found that CBD exerts antitumor effects by regulating the cell cycle, inducing apoptosis and autophagy in tumor cells, and inhibiting tumor cell invasion, migration, and angiogenesis. The abstract suggests CBD has therapeutic potential for various diseases, including tumors.", "population_specificity": "Not specified (review article, not a clinical study)", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:10:49.540277+00:00"}
{"study_id": 50547, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to review the current literature on CBD's effects on the cardiovascular system, focusing on its physiological impacts and therapeutic potential in pathological conditions.", "results_summary": "The study highlights CBD's potential therapeutic benefits for cardiovascular diseases, including anti-inflammatory, vasodilatory, anti-fibrotic, and antioxidant properties, with positive outcomes in conditions like diabetic cardiomyopathy, myocarditis, doxorubicin-induced cardiotoxicity, and ischemia-reperfusion injury.", "population_specificity": "Pre-clinical studies (cellular and animal models) and human clinical trials.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:10:49.899007+00:00"}
{"study_id": 50551, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to explore the potential of cannabinoids, including CBD, as a therapeutic option for post-COVID condition (PCC) by examining their antioxidative and anti-inflammatory properties.", "results_summary": "The study found that phytocannabinoids like CBD exhibit significant antioxidative and anti-inflammatory properties, suggesting they could be effective adjuvants for PCC, either alone or in combination with other therapies. However, further studies are needed to confirm these findings.", "population_specificity": "Individuals with post-COVID condition (PCC) experiencing neuroinflammation-related symptoms.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:10:52.389369+00:00"}
{"study_id": 50549, "supplement_id": 977, "safety_score": "75", "efficacy_score": 80, "quality_score": 65, "study_goal": "The researchers aimed to determine whether adjunctive use of CBD improves quality of life and psychological well-being in adults with treatment-resistant epilepsy.", "results_summary": "The study found statistically significant improvements in quality of life and anxiety symptoms, as well as reduced adverse events, but no significant improvement in depression symptoms. Urinalysis confirmed CBD presence post-intervention.", "population_specificity": "Adults with treatment-resistant epilepsy (TRE).", "effective_dosage": "Not specified", "study_duration": "Approximately five months of CBD use following one month of baseline.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:10:52.874479+00:00"}
{"study_id": 50553, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 65, "study_goal": "The researchers aimed to consolidate and compare the effects and pharmacokinetic properties of CBD between adult and paediatric epilepsy patients.", "results_summary": "The study found that paediatric patients had a more significant reduction in seizure severity compared to adults, with differences in pharmacokinetic properties such as volume of distribution and metabolism. However, insufficient data was available to compare absorption and elimination between the two populations.", "population_specificity": "Adult and paediatric epilepsy patients.", "effective_dosage": "Not specified.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:10:53.759323+00:00"}
{"study_id": 50555, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 85, "study_goal": "The researchers aimed to determine whether a low oral dose (150 mg) of CBD could reduce acute psychosocial stress, situational anxiety, motion sickness, and cybersickness in healthy individuals.", "results_summary": "The abstract describes a study protocol but does not report results; the study will test whether CBD reduces nausea and attenuates stress responses compared to placebo.", "population_specificity": "Healthy individuals (n=74)", "effective_dosage": "150 mg of CBD, administered once 90 minutes before VR challenges", "study_duration": "Single-dose intervention", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:10:54.184938+00:00"}
{"study_id": 50554, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 30, "quality_score": 75, "study_goal": "The researchers aimed to determine the effects of short-term CBD supplementation on performance, muscle damage, and inflammatory processes in well-trained athletes.", "results_summary": "The study found that performance level influenced responses to CBD, but no clear effects of either CBD product were observed, indicating further research is needed to assess long-term impacts.", "population_specificity": "Well-trained athletes (17 subjects, advanced or highly advanced).", "effective_dosage": "60 mg of CBD oil or solubilisate per training session.", "study_duration": "Six-day high-intensity training protocol per intervention phase, with three total phases separated by four-week washout periods.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:10:54.594732+00:00"}
{"study_id": 50558, "supplement_id": 977, "safety_score": "75", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the efficacy and safety of CBD in pediatric patients with Dravet Syndrome based on data from ten clinical trials.", "results_summary": "CBD demonstrated substantial reductions in seizure frequency, with some patients achieving seizure freedom, and showed an acceptable safety profile with manageable adverse events.", "population_specificity": "Pediatric patients diagnosed with Dravet Syndrome.", "effective_dosage": "Not Assessed", "study_duration": "Not Assessed", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:10:56.686593+00:00"}
{"study_id": 50557, "supplement_id": 977, "safety_score": "75", "efficacy_score": 70, "quality_score": 85, "study_goal": "The researchers aimed to assess symptom intensity, microbiome profile, cytokines, bacterial metabolites, pharmacokinetics, and pharmacogenetics in breast cancer patients treated with cannabis oil containing CBD and THC.", "results_summary": "The study found that CBD and THC doses were generally well tolerated, with overall symptom benefit observed in total symptom distress scores. Further analysis will explore microbiome, cytokine, and metabolite changes, along with pharmacokinetic and pharmacogenetic profiles.", "population_specificity": "Breast cancer patients undergoing chemotherapy at King Chulalongkorn Memorial Hospital, Thailand.", "effective_dosage": "Ganja Oil (THC 0.08 mg/drop, CBD 0.02 mg/drop) and Metta Osot (THC 3 mg/drop).", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:10:59.521731+00:00"}
{"study_id": 50556, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 35, "quality_score": 75, "study_goal": "The researchers aimed to determine whether acute CBD use impairs cognitive and psychomotor performance compared to placebo, using controlled human laboratory studies.", "results_summary": "The meta-analysis found a statistically significant but small effect size (Hedges' g = 0.122) for impaired performance following acute CBD consumption compared to placebo, with subjective measures like self-reported sedation showing larger differences than objective tasks.", "population_specificity": "Adults in clinical trials measuring acute CBD effects.", "effective_dosage": "Not specified", "study_duration": "Effects measured within 0-8 hours of administration.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:11:00.327724+00:00"}
{"study_id": 50559, "supplement_id": 977, "safety_score": "75", "efficacy_score": 65, "quality_score": 85, "study_goal": "The researchers aimed to investigate the acute effects of a standard dose of CannEpil\u00ae (100 mg CBD and 5 mg THC) on neurocognition, attention, and mood in healthy individuals.", "results_summary": "CannEpil impaired visuospatial working memory and delayed pattern recognition but increased subjective contentedness and amicability. Drowsiness was reported by 23% of participants, with no significant correlations between plasma concentrations of CBD/THC and observed effects.", "population_specificity": "31 healthy participants (16 female, 15 male), aged 21-58 years.", "effective_dosage": "1 mL sublingual dose (100 mg CBD and 5 mg THC).", "study_duration": "Two-week experimental protocol.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:11:01.436600+00:00"}
{"study_id": 50561, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 60, "study_goal": "The researchers aimed to investigate the neuroprotective effects of CBD and other Cannabis sativa L. derivatives on central nervous system diseases through interactions with endocannabinoid system-related receptors and other molecular targets.", "results_summary": "The study found that CBD and other Cannabis sativa L. derivatives exhibit neuroprotective effects on central nervous system diseases, likely due to their interactions with endocannabinoid system-related receptors and other targets like 5-HT.", "population_specificity": "Not specified in the abstract.", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:11:01.833185+00:00"}
{"study_id": 50560, "supplement_id": 977, "safety_score": "65", "efficacy_score": 30, "quality_score": 75, "study_goal": "The researchers aimed to study the short-term efficacy and tolerability of a high CBD/low THC cannabis extract in individuals with Parkinson's disease to gather preliminary data for a longer trial.", "results_summary": "The study found no significant difference in motor symptom improvement between the CBD/THC group and placebo, with some assessments showing a strong placebo response. Sleep, cognition, and daily activities showed effects favoring placebo, and mild adverse events were more frequent in the CBD/THC group.", "population_specificity": "Individuals with Parkinson's disease (motor MDS-UPDRS \u226520) who tested negative for cannabis use.", "effective_dosage": "Final dose of 2.5 mg/kg/day (mean 191.8 mg CBD and 6.4 mg THC daily).", "study_duration": "2 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:11:02.477078+00:00"}
{"study_id": 50562, "supplement_id": 977, "safety_score": "80", "efficacy_score": 70, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the potential benefits of cannabinoids, particularly CBD, in treating behavioral and psychological symptoms of dementia (BPSD) and their feasibility in elderly populations.", "results_summary": "Recent studies using higher doses of THC/CBD-based oral medication showed promising results for improving sleep, agitation, and anxiety in BPSD, with feasibility and safety in elderly polymedicated patients. Older studies using low-dose synthetic THC showed no positive effects.", "population_specificity": "Elderly patients with dementia and behavioral and psychological symptoms (BPSD).", "effective_dosage": "Higher doses (specific amounts not mentioned).", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:11:03.200588+00:00"}
{"study_id": 50563, "supplement_id": 977, "safety_score": "85", "efficacy_score": 75, "quality_score": 90, "study_goal": "The researchers aimed to examine the efficacy, safety, and quality of life impact of a 12-week CBD treatment for patients with moderate-to-severe Cannabis Use Disorder (CUD).", "results_summary": "The study suggests that CBD reduced non-prescribed cannabis use in people with CUD, with potential benefits for mental health and cognitive impairments. Secondary endpoints included improvements in withdrawal severity, cravings, and quality of life.", "population_specificity": "250 adults with moderate-to-severe CUD (targeting 20% Aboriginal participants) from drug and alcohol clinics in NSW and VIC, Australia.", "effective_dosage": "4 mL (100 mg/mL) of CBD daily.", "study_duration": "12 weeks, with follow-up at 24 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:11:03.912324+00:00"}
{"study_id": 50566, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the efficacy of Cannabidiol (CBD) as an add-on anti-seizure medication for reducing convulsive seizure frequency in patients with Dravet syndrome.", "results_summary": "CBD was found to be superior to placebo in achieving at least a 50% and 75% reduction in convulsive seizure frequency, though it did not significantly reduce monthly convulsive seizure frequency (MCSF). It was considered effective but showed prominent inter-individual variability.", "population_specificity": "Patients with Dravet syndrome (633 participants across six randomized controlled trials).", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:11:05.799795+00:00"}
{"study_id": 50569, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 20, "quality_score": 75, "study_goal": "The researchers aimed to determine whether CBD treatment affects disease progression and survival in patients with advanced cancer.", "results_summary": "The study found no significant difference in disease progression or survival between CBD and placebo groups over 56 days. Disease progression at day 14 was highly predictive of mortality.", "population_specificity": "Patients with advanced cancer enrolled in the MEDCAN-1 Study.", "effective_dosage": "Not specified", "study_duration": "56 days", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:11:08.557501+00:00"}
{"study_id": 50568, "supplement_id": 977, "safety_score": "90", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the anti-inflammatory and antimicrobial effects of CBD on human gingival fibroblasts and assess its clinical efficacy in subjects with periodontitis.", "results_summary": "CBD reduced inflammation in human gingival fibroblasts and exhibited antimicrobial activity against Porphyromonas gingivalis. The clinical trial showed statistically significant improvements in periodontal indices with CBD use compared to placebo.", "population_specificity": "Human gingival fibroblasts and subjects with periodontitis (n=90).", "effective_dosage": "1% (w/w) CBD in dental gel and toothpaste.", "study_duration": "56 days.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:11:08.727303+00:00"}
{"study_id": 50567, "supplement_id": 977, "safety_score": "70", "efficacy_score": 80, "quality_score": 85, "study_goal": "The researchers aimed to determine whether a combination of THC and CBD could reduce tic severity and associated symptoms in individuals with severe Tourette syndrome.", "results_summary": "The study found that treatment with THC and CBD significantly reduced tic severity compared to placebo, with a greater decrease in symptoms under active treatment. Some participants experienced cognitive difficulties, including slowed mentation and memory lapses.", "population_specificity": "Individuals with severe Tourette syndrome (22 participants, eight female).", "effective_dosage": "Oral oil containing 5 mg/ml of THC and 5 mg/ml of CBD, with escalating doses over 6 weeks.", "study_duration": "6-week treatment periods separated by a 4-week washout.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:11:08.934440+00:00"}
{"study_id": 50572, "supplement_id": 977, "safety_score": "85", "efficacy_score": 70, "quality_score": 75, "study_goal": "The researchers aimed to review clinical studies on the effects of CBD in psychiatric conditions to assess its safety and efficacy.", "results_summary": "The abstract highlights CBD's diverse effects in psychiatric conditions and an excellent safety profile compared to standard treatments, though evidence from randomized clinical trials remains limited for most indications.", "population_specificity": "Patients with psychiatric conditions (specific conditions not detailed in the abstract).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:11:10.507953+00:00"}
{"study_id": 50570, "supplement_id": 977, "safety_score": "40", "efficacy_score": 70, "quality_score": 80, "study_goal": "The researchers aimed to review CBD pharmacokinetics, mechanisms of hepatotoxicity, and safety risks to inform future modeling efforts for understanding CBD toxicity.", "results_summary": "The study found that CBD causes dose-dependent hepatocellular toxicity at therapeutic doses, particularly in patients taking valproate, and highlights the need for improved understanding of CBD-induced hepatotoxicity. Current pharmacokinetic and in vitro models are being used to explore these mechanisms.", "population_specificity": "Children aged 1 year and older with Lennox-Gastaut syndrome, Dravet syndrome, or tuberous sclerosis complex.", "effective_dosage": "Therapeutic doses (specific amounts not provided).", "study_duration": "Not specified.", "interactions": "Increased hepatotoxicity risk when taken with valproate.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:11:11.717542+00:00"}
{"study_id": 50573, "supplement_id": 977, "safety_score": "75", "efficacy_score": 80, "quality_score": 85, "study_goal": "The researchers aimed to review the pharmacokinetics, safety profile, and therapeutic potential of Cannabidiol (CBD), including its interactions with biological systems and anti-inflammatory effects.", "results_summary": "The study highlights CBD's diverse therapeutic potential, including its role in immune system regulation and anti-inflammatory effects via interactions with the endocannabinoid system and ion channels. It also discusses CBD's pharmacological profile, safety, and dosage recommendations, positioning it as a promising candidate for clinical applications.", "population_specificity": "Not specified (review article)", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:11:11.984549+00:00"}
{"study_id": 50571, "supplement_id": 977, "safety_score": "75", "efficacy_score": 68, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the efficacy and safety of Cannabidiol (CBD) as an adjunctive treatment for focal epilepsy, Dravet syndrome (DS), and Lennox-Gastaut syndrome (LGS) compared to other antiseizure medications.", "results_summary": "CBD showed good efficacy for LGS (SUCRA 88.4) and DS (SUCRA 66.2) but was not more effective than placebo for adult focal epilepsy. Safety data were not explicitly detailed, but CBD was included in comparisons without significant adverse event highlights.", "population_specificity": "Adult patients with focal epilepsy and adolescents with DS, LGS, or tuberous sclerosis complex (TSC).", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:11:12.584317+00:00"}
{"study_id": 50576, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 65, "study_goal": "The researchers aimed to explore the potential of CBD in delaying aging and treating Alzheimer's disease (AD) by examining its antioxidant and anti-inflammatory properties.", "results_summary": "The study suggests CBD may help prevent aging and treat AD by addressing oxidative stress and chronic inflammation, though specific clinical outcomes are not detailed.", "population_specificity": "Not specified (focus on aging and Alzheimer's disease mechanisms).", "effective_dosage": "Not provided", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:11:12.646267+00:00"}
{"study_id": 50577, "supplement_id": 977, "safety_score": "80", "efficacy_score": 60, "quality_score": 70, "study_goal": "The researchers aimed to evaluate the potential of CBD and CBD-rich cannabis extracts in managing core symptoms and behavioral deficits in autism spectrum disorder (ASD).", "results_summary": "Uncontrolled case series reported improvements in core ASD symptoms and behavioral challenges, while placebo-controlled studies showed mixed efficacy results. Safety and tolerability were relatively high across studies.", "population_specificity": "Children with autism spectrum disorder (ASD) and Fragile X syndrome.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:11:15.897461+00:00"}
{"study_id": 50579, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 75, "study_goal": "The researchers aimed to identify biological mechanisms affected by cannabis use, including CBD, that may trigger bipolar disorder type-I (BDI).", "results_summary": "The study identified molecular and cellular mechanisms altered by CBD, such as neural development, inflammatory pathways, and the endocannabinoid system, which were also found in BDI samples, suggesting potential diagnostic and therapeutic targets.", "population_specificity": "Cannabis users and human-derived cells exposed to THC or CBD, as well as BDI samples.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:11:16.942194+00:00"}
{"study_id": 50578, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to examine the effectiveness of CBD on severe behavioral manifestations in three rare genetic neurodevelopmental disorders (TSC, MPS III, and FXS) using an innovative N-of-1 trial design.", "results_summary": "The study design suggests potential effectiveness of CBD for severe behavioral manifestations in RGNDs, but results are pending as the abstract describes the planned methodology rather than outcomes. The primary outcome measure is irritability, with secondary measures including behavioral, psychiatric, and disease-specific outcomes.", "population_specificity": "30 patients aged \u22656 years with confirmed TSC, MPS III, or FXS and severe behavioral manifestations.", "effective_dosage": "Oral CBD up to a maximum of 25 mg/kg/day, twice daily.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:11:18.784523+00:00"}
{"study_id": 50581, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 65, "study_goal": "The researchers aimed to summarize existing data on CBD's potential role in managing vascular diseases, focusing on molecular targets, pharmacokinetics, therapeutic effects, and side effects.", "results_summary": "CBD demonstrated anti-anxiety, anti-oxidation, and anti-inflammatory properties, with potential therapeutic effects on atherosclerosis, stress-induced hypertension, diabetes-related vasculopathy, ischemia-reperfusion injury, and vascular damage from smoking and alcohol abuse.", "population_specificity": "Not specified (review of existing studies)", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:11:19.662502+00:00"}
{"study_id": 50582, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to consolidate information on the obesogenic and cardiometabolic effects of prenatal cannabis exposure, including the role of CBD and THC ratios.", "results_summary": "The study found that prenatal cannabis exposure is associated with low birth weight and rapid postnatal weight gain, but did not specifically isolate CBD's effects. More research is needed on dose, timing, and composition (e.g., CBD:THC ratio).", "population_specificity": "Pregnant individuals and their offspring", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:11:20.146085+00:00"}
{"study_id": 50580, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 40, "quality_score": 75, "study_goal": "The researchers aimed to determine whether 150 mg of nightly CBD supplementation could improve sleep outcomes and psychological health in individuals with primary insomnia compared to placebo.", "results_summary": "The study found no significant differences between CBD and placebo in insomnia severity, sleep-onset latency, sleep efficiency, or wake after sleep onset, but CBD was associated with greater well-being.", "population_specificity": "Individuals with primary insomnia (n=30, 15 per group).", "effective_dosage": "150 mg nightly, administered sublingually.", "study_duration": "2-week randomized dosing phase following a 1-week placebo run-in.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:11:20.406933+00:00"}
{"study_id": 50583, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to investigate pregnant women's attitudes, beliefs, and the prevalence of clinician counseling regarding cannabinoid (including CBD) use during pregnancy.", "results_summary": "The study found that pregnant women lacked knowledge about CBD use during pregnancy (77%), had negative beliefs about its impact on their fetus and birth outcomes, and primarily relied on the internet for information. Over 60% reported not receiving counseling on cannabinoid use during prenatal care.", "population_specificity": "Pregnant women receiving prenatal care at obstetrics and gynecology clinics in Milwaukee, Wisconsin (n=95, average age 29, 54% non-White).", "effective_dosage": "Not available", "study_duration": "Not applicable (observational study)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:11:21.431694+00:00"}
{"study_id": 50584, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 20, "quality_score": 65, "study_goal": "The researchers aimed to evaluate the clinical evidence for phytocannabinoids, including CBD, in treating neuropathic pain.", "results_summary": "The study found that CBD showed no analgesic effect over placebo in two small, short-duration trials, while THC/CBD combinations had mixed results with some pain reduction but not always statistically significant.", "population_specificity": "Patients with neuropathic pain, including diabetic peripheral neuropathy, chemotherapy-induced neuropathy, and multiple sclerosis-related neuropathy.", "effective_dosage": "Not specified", "study_duration": "Short duration (exact length not specified)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:11:21.565780+00:00"}
{"study_id": 50585, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the pharmacokinetics and pharmacodynamics of orally administered cannabis-based medicine (CBM) in patients with multiple sclerosis (MS) experiencing neuropathic pain and spasticity.", "results_summary": "The study assessed PK and PD in a probable steady state of CBM but did not report specific efficacy outcomes in the provided abstract. The trial was randomized, double-blinded, and placebo-controlled, suggesting methodological rigor.", "population_specificity": "23 patients with multiple sclerosis (mean age 52 years, 17 female).", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:11:25.333034+00:00"}
{"study_id": 50586, "supplement_id": 977, "safety_score": "80", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to explore the effectiveness of CBD augmentation on symptoms and neurocognition in early psychosis, while also investigating its mechanism of action and predictors of treatment response.", "results_summary": "The study hypothesized that CBD would improve symptoms, neurocognition, and secondary measures like neurohormones, inflammation, eating behaviors, and information processing, though results are pending as the trial is ongoing. Anecdotal reports from patients suggest subjective improvements in stress, anxiety, and coping abilities.", "population_specificity": "120 individuals in the early stages of psychosis.", "effective_dosage": "1000 mg of CBD daily.", "study_duration": "8 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:11:25.822323+00:00"}
{"study_id": 50587, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 60, "quality_score": 50, "study_goal": "The researchers aimed to review the potential therapeutic applications of cannabinoids, including CBD, for various skin conditions and highlight areas for future research.", "results_summary": "The abstract suggests that cannabinoids, including CBD, show promise for treating eczema, psoriasis, acne, pruritus, hair disorders, and skin cancer, but most data are preclinical, and large-scale clinical trials are lacking.", "population_specificity": "Not specified (preclinical and theoretical human applications).", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:11:26.624333+00:00"}
{"study_id": 50588, "supplement_id": 977, "safety_score": "85", "efficacy_score": 70, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the safety, tolerability, and preliminary effects of a CBD-containing formulation on recovery in exercise-trained individuals.", "results_summary": "The formulation reduced interference of delayed-onset muscle soreness (DOMS) on daily activities but showed no significant effects on objective recovery measures, sleep quality, or mood disturbance. Adverse events were minimal and comparable between active and placebo groups.", "population_specificity": "Exercise-trained individuals", "effective_dosage": "35 mg CBD (combined with CBG, BCP, BCAAs, and magnesium citrate)", "study_duration": "Not specified in the abstract", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:11:27.943012+00:00"}
{"study_id": 50590, "supplement_id": 977, "safety_score": "80", "efficacy_score": 70, "quality_score": 60, "study_goal": "The researchers aimed to review the pharmacodynamic and pharmacokinetic features of CBD and its potential therapeutic effects on selected diseases, particularly focusing on aging and Alzheimer's disease.", "results_summary": "The study highlights CBD's potential beneficial effects on aging and Alzheimer's disease, emphasizing its lack of dependence risk compared to THC. It discusses underlying mechanisms but does not provide specific clinical trial results.", "population_specificity": "Not specified (review article, not a clinical study).", "effective_dosage": "Not specified.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:11:28.195690+00:00"}
{"study_id": 50592, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to review the role of cannabinoids, particularly CBD, in treating epilepsy and seizures, and explore potential therapeutic benefits for other neurological and psychiatric disorders.", "results_summary": "The study found that CBD has a significant role in treating epilepsy and seizures, supported by preclinical and clinical investigations, and suggests potential benefits for other neurological and psychiatric conditions.", "population_specificity": "Not specified (review of preclinical animal studies and clinical investigations)", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:11:29.158134+00:00"}
{"study_id": 50589, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to assess the effectiveness and safety of CBD as an analgesic for patients with emergency acute dental pain.", "results_summary": "Both CBD groups (10 mg/kg and 20 mg/kg) showed significant pain reduction compared to baseline and placebo, with a maximum median VAS pain reduction of 73% at 180 minutes. Secondary outcomes included pain intensity differences, onset of relief, and bite force changes, but psychoactive effects and adverse events were not detailed.", "population_specificity": "Sixty-one patients with moderate to severe toothache.", "effective_dosage": "10 mg/kg and 20 mg/kg, single oral dose.", "study_duration": "3 hours.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:11:30.435916+00:00"}
{"study_id": 50591, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to examine the pre-clinical data on nonintoxicating cannabinoids (niCBs), including CBD, for treating abdominal pain, focusing on non-cannabinoid receptor (CBR) mechanisms.", "results_summary": "The study found that niCBs like CBD show potential for addressing abnormal intestinal motility, inflammation, and pain, often through non-CBR pathways. However, clinical research on CBD has yielded mixed results, and its efficacy may be enhanced when combined with other cannabinoids via the entourage effect.", "population_specificity": "Pre-clinical data (not specified human or animal models).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:11:30.848201+00:00"}
{"study_id": 50594, "supplement_id": 977, "safety_score": "75", "efficacy_score": 80, "quality_score": 85, "study_goal": "The researchers aimed to evaluate CBD's therapeutic potential for neurological conditions, including epilepsy, multiple sclerosis, Parkinson's disease, and Alzheimer's disease, by examining its pharmacological effects and mechanisms of action.", "results_summary": "The study found that CBD exhibits neuroprotective, anti-inflammatory, and antioxidative properties, with promising results in preclinical and clinical settings for managing neurological disorders. However, regulatory challenges and inconsistent findings highlight the need for further research on efficacy and optimal dosing.", "population_specificity": "Patients with neurological conditions (epilepsy, multiple sclerosis, Parkinson's disease, Alzheimer's disease) and preclinical models (animal and in vitro studies).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:11:35.239957+00:00"}
{"study_id": 50595, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to determine whether a single dose of CBD could normalize elevated hippocampal blood flow in individuals at Clinical High Risk for Psychosis (CHR).", "results_summary": "The study found that placebo-treated CHR patients had significantly higher hippocampal blood flow compared to healthy controls, while a single 600 mg dose of CBD partially normalized this hyperperfusion. CBD showed potential as a treatment for hippocampal hyperperfusion in CHR patients.", "population_specificity": "Individuals at Clinical High Risk for Psychosis (CHR) and healthy controls.", "effective_dosage": "600 mg single oral dose.", "study_duration": "Single dose administration.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:11:35.671835+00:00"}
{"study_id": 50596, "supplement_id": 977, "safety_score": "85", "efficacy_score": 70, "quality_score": 75, "study_goal": "The researchers aimed to investigate the effects of 50 mg oral CBD on mental health, sleep quality, and immune cell function in healthy, college-aged individuals over 8 weeks.", "results_summary": "The study found no significant changes in body weight, BMI, or body fat percentage but suggested potential improvements in sleep quality and NK immunosurveillance in healthy young adults.", "population_specificity": "Healthy, college-aged individuals (average age 25.9 \u00b1 6.1 years).", "effective_dosage": "50 mg daily oral CBD.", "study_duration": "8 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:11:36.514296+00:00"}
{"study_id": 50593, "supplement_id": 977, "safety_score": "75", "efficacy_score": 60, "quality_score": 70, "study_goal": "The researchers aimed to assess the pharmacokinetics, pharmacodynamics, and potential drug interactions of cannabinoid drugs, including CBD, particularly in multimorbid patients taking multiple medications.", "results_summary": "The study found that CBD's metabolism is less dependent on cytochrome P450 enzymes than THC, and clinically relevant drug interactions are likely only at high doses (above 300 mg/day). Potential drug interactions with CBD are generally minor at low or moderate doses but can be intensified or weakened by strong CYP inhibitors or inductors.", "population_specificity": "Multimorbid patients taking multiple drugs.", "effective_dosage": "Clinically relevant interactions noted at doses above 300 mg/day.", "study_duration": "Not specified.", "interactions": "Strong CYP3A4 inhibitors (e.g., verapamil, clarithromycin) and inductors (e.g., rifampicin, carbamazepine) can affect CBD's plasma concentrations. CBD inhibits CYP2C and CYP3A4.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:11:36.941170+00:00"}
{"study_id": 50597, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to review the preclinical and clinical therapeutic applications of CBD, CBG, and CBN, particularly their potential in treating neuropathic pain.", "results_summary": "The study found that cannabinoids, including CBD, exhibit neuroprotective effects and may alleviate neuropathic pain by modulating neurotransmitter release, reducing inflammation, and correcting autophagy defects. Preclinical and clinical evidence supports their therapeutic potential, though ongoing trials are needed for further validation.", "population_specificity": "Patients with neuropathic pain due to nerve injury, autoimmune disorders, metabolic conditions, or chemotherapy toxicity.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:11:37.015384+00:00"}
{"study_id": 50600, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": null, "study_goal": "The abstract does not specify the researchers' goal regarding Cannabidiol (CBD).", "results_summary": "The abstract does not provide results regarding Cannabidiol (CBD)'s effects.", "population_specificity": "Not specified in the abstract.", "effective_dosage": "Not provided.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:11:37.639954+00:00"}
{"study_id": 50599, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 60, "quality_score": 70, "study_goal": "The researchers aimed to explore the potential utility of CBD for managing COVID-19 patients, particularly those with ARDS, by examining its anti-inflammatory properties.", "results_summary": "The abstract suggests CBD may have anti-inflammatory properties that could help manage cytokine storms in COVID-19 patients, but it does not provide specific clinical results or outcomes. The study reviews existing knowledge rather than presenting new experimental data.", "population_specificity": "COVID-19 patients, particularly those with ARDS.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:11:38.451540+00:00"}
{"study_id": 50598, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 20, "quality_score": 85, "study_goal": "The researchers aimed to determine whether CBD moderates the effects of THC on attentional bias and explicit liking in infrequent cannabis users.", "results_summary": "The study found that CBD had no significant effect on attentional bias or explicit liking at any tested dose, and THC alone increased attentional bias toward cannabis without affecting explicit liking.", "population_specificity": "Forty-six infrequent cannabis users (cannabis use <1 per week).", "effective_dosage": "10 mg THC with 0 mg, 10 mg, 20 mg, or 30 mg CBD (ratios: 0:1, 1:1, 2:1, 3:1).", "study_duration": "Four sessions (cross-over design).", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:11:38.736563+00:00"}
{"study_id": 50603, "supplement_id": 977, "safety_score": "80", "efficacy_score": 40, "quality_score": 60, "study_goal": "The researchers aimed to review the effects of CBD alone on acute and chronic low back pain (LBP) to assess its potential as a therapeutic agent.", "results_summary": "The study found limited evidence for CBD's effectiveness in treating acute LBP, with one clinical trial showing no superiority over placebo. For chronic LBP, most studies suggested a beneficial effect, but rigorous evidence is lacking.", "population_specificity": "Patients with acute and chronic low back pain.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:11:43.496152+00:00"}
{"study_id": 50601, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers sought to determine the effects of CBD, alone and in combination with CBN, on sleep quality in individuals with poor self-rated sleep.", "results_summary": "The study evaluated CBD's impact on sleep quality, onset latency, awakenings, WASO, sleep disturbance, and daytime fatigue, but specific results for CBD alone were not detailed in the abstract.", "population_specificity": "Adults aged 18-55 who self-rated their sleep quality as \"very poor\" or \"poor.\"", "effective_dosage": "10 mg, 20 mg, and 100 mg CBD combined with 20 mg CBN, administered nightly.", "study_duration": "7 consecutive nights", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:11:44.762727+00:00"}
{"study_id": 50609, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to determine cannabinoid levels in blood and assess driving-related ability after single and repetitive vaporization of CBD-rich cannabis.", "results_summary": "The abstract does not provide specific results regarding CBD's effects.", "population_specificity": "Not specified in the abstract.", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:11:45.533177+00:00"}
{"study_id": 50608, "supplement_id": 977, "safety_score": "85", "efficacy_score": 80, "quality_score": 75, "study_goal": "The researchers aimed to summarize the pharmacokinetics, mechanisms of action, and physiological effects of CBD based on pre-clinical and human studies.", "results_summary": "CBD demonstrated therapeutic potential for various disorders, including anxiety, chronic pain, psychiatric pathologies, cardiovascular diseases, and cancer, with a generally safe profile. It affects inflammation, oxidative damage, cell survival, pain, vasodilation, and excitability at molecular, cellular, and organ levels.", "population_specificity": "Pre-clinical studies (animal models) and human trials (general).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:11:45.603606+00:00"}
{"study_id": 50605, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 50, "study_goal": "The researchers aimed to summarize the evidence on the effects of CBD on pain and inflammation of various causes.", "results_summary": "The study found mixed results regarding CBD's effectiveness in relieving pain due to variations in administration routes and treatment regimens. However, positive treatment results were observed in all publications examining CBD's effect on arthritis, while its anti-inflammatory effect on the intestinal system was negligible.", "population_specificity": "Not specified (studies included various etiopathogenesis of pain, such as chronic, neuropathic, and inflammatory pain).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:11:45.947336+00:00"}
{"study_id": 50604, "supplement_id": 977, "safety_score": "72", "efficacy_score": 85, "quality_score": 68, "study_goal": "The researchers aimed to evaluate the efficacy and safety of highly purified CBD for treating drug-resistant epilepsy across various etiologies in patients over 2 years of age.", "results_summary": "The study found a mean seizure reduction of 67.8%, with 68.8% of patients experiencing \u226550% reduction in seizure frequency and 11.5% achieving seizure freedom. Adverse events occurred in 28.2% of patients, but the drug-retention rate was 78.2%.", "population_specificity": "Patients >2 years old with drug-resistant epilepsy of mainly structural and genetic etiologies (median age 24 years).", "effective_dosage": "Not specified", "study_duration": "Median treatment time was 14 months (IQR=10-17).", "interactions": "No significant impact of concomitant clobazam use on efficacy or safety.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:11:47.428341+00:00"}
{"study_id": 50610, "supplement_id": 977, "safety_score": "90", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the safety and efficacy of low-dose CBD (Epidiolex) as adjunctive therapy for idiopathic adult-onset blepharospasm (BPS) and develop an objective assessment methodology.", "results_summary": "CBD safely improved several BPS kinematic parameters, reducing eyelid closure amplitude and duration while increasing closure velocity, though clinical scale improvements were not statistically significant.", "population_specificity": "12 patients with idiopathic adult-onset blepharospasm undergoing routine botulinum toxin therapy.", "effective_dosage": "Low dose (specific amount not stated), daily.", "study_duration": "6 months (two 3-month cycles).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:11:47.696486+00:00"}
{"study_id": 50612, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 60, "quality_score": 75, "study_goal": "The researchers aimed to assess the effects of acute and repeated CBD administration (300mg vs. 50mg vs. placebo) on worry severity and anxiety symptoms in individuals with elevated trait worry.", "results_summary": "Acute CBD dosing had no effect on worry or anxiety symptoms. Repeated administration of 300mg CBD reduced anxiety symptoms over 2 weeks compared to placebo but did not affect worry severity.", "population_specificity": "63 individuals with elevated trait worry.", "effective_dosage": "300mg (empirically-derived high dose) and 50mg (commercially-derived dose).", "study_duration": "2 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:11:47.736071+00:00"}
{"study_id": 50613, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the safety and efficacy of CBD as a pharmaceutical intervention for neurodevelopmental disorders by reviewing nine published RCTs.", "results_summary": "Several trials indicated potential efficacy of CBD, but results were inconsistent across studies, making it difficult to confidently recommend clinical usage. The lack of comparable RCTs leaves CBD's suitability for neurodevelopmental disorders largely undetermined.", "population_specificity": "Individuals diagnosed with attention deficit hyperactivity disorder, autism spectrum disorder, intellectual disability, Tourette Syndrome, and complex motor disorders.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:11:52.066176+00:00"}
{"study_id": 50616, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to review the impact of cannabinoids, including CBD, on angiogenesis and their potential therapeutic applications for angiogenesis-related pathologies.", "results_summary": "The study found that cannabinoids, including CBD, can modulate angiogenesis, with conflicting reports on their effects. However, their ability to influence the angiogenic process is confirmed, suggesting potential therapeutic routes for related diseases.", "population_specificity": "Not specified (review of existing data)", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:11:53.048673+00:00"}
{"study_id": 50617, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 70, "study_goal": "The researchers aimed to investigate the effects of CBD on Lean Body Mass (LBM) and taste alterations during oxaliplatin- or paclitaxel-based chemotherapy.", "results_summary": "CBD showed no effect on LBM but improved the ability to differentiate between weak and strong sweetness in chemotherapy patients, while the control group lost this ability over time.", "population_specificity": "Patients undergoing oxaliplatin- or paclitaxel-based chemotherapy.", "effective_dosage": "300 mg/day", "study_duration": "8 days", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:11:53.840559+00:00"}
{"study_id": 50615, "supplement_id": 977, "safety_score": "75", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to compare the effects of pharmaceutical CBD versus placebo in patients with idiopathic or diabetic gastroparesis, focusing on symptom relief and gastric function.", "results_summary": "CBD significantly reduced gastroparesis symptoms (e.g., vomiting, meal intolerance, overall severity) and improved liquid nutrient tolerance, despite slowing gastric emptying. Adverse events included diarrhea, fatigue, headache, and nausea.", "population_specificity": "Patients with idiopathic or diabetic (type 1 or 2) gastroparesis and delayed gastric emptying of solids.", "effective_dosage": "Escalated to 20 mg/kg/day, administered twice daily.", "study_duration": "4 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:11:54.627033+00:00"}
{"study_id": 50619, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 70, "study_goal": "The researchers aimed to synthesize evidence on CBD's potential as a harm reduction tool for people with problematic substance use, focusing on cravings, anxiety, and well-being.", "results_summary": "Low-quality evidence suggests CBD may reduce drug cravings and anxiety in opioid use disorder and improve mood and well-being, but it is likely more effective as an adjunct rather than a standalone treatment.", "population_specificity": "Adults with problematic substance use, particularly opioid use disorder.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:11:55.269612+00:00"}
{"study_id": 50614, "supplement_id": 977, "safety_score": "90", "efficacy_score": 80, "quality_score": 70, "study_goal": "The researchers aimed to assess the efficacy and tolerance of cannabidiol (CBD) as adjunctive therapy for Rett syndrome (RTT) patients with epilepsy.", "results_summary": "CBD reduced seizures in 70% of patients, with one becoming seizure-free, two experiencing >75% reduction, and four showing >50% decrease. It also improved agitation, anxiety, and spasticity in some patients, with minimal adverse effects.", "population_specificity": "46 Rett syndrome patients, 26 of whom had epilepsy (10 treated with CBD).", "effective_dosage": "Median dose of 15 mg/kg/day.", "study_duration": "Median treatment duration was 13 months (range: 1-32 months).", "interactions": "Used in combination with clobazam in 50% of cases.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:11:55.492580+00:00"}
{"study_id": 50621, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the long-term effects of the DehydraTECH2.0 CBD formulation on plasma and urine CBD concentrations and its metabolites in hypertensive volunteers.", "results_summary": "The study found that the plasma concentration ratio of CBD/7-OH-CBD was significantly higher after 5 weeks of use compared to 2.5 weeks, indicating potential sustained bioavailability of the new formulation.", "population_specificity": "62 hypertensive volunteers", "effective_dosage": "Not specified", "study_duration": "12 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:11:55.853450+00:00"}
{"study_id": 50620, "supplement_id": 977, "safety_score": "80", "efficacy_score": 60, "quality_score": 75, "study_goal": "The researchers aimed to investigate the effects of 8 weeks of CBD supplementation on health-related fitness, physical activity, cognitive health, psychological wellbeing, and CRP concentrations in healthy individuals.", "results_summary": "The study found no significant differences between CBD and placebo groups in body composition, aerobic fitness, muscular strength, physical activity, cognitive health, psychological wellbeing, or CRP levels. However, the CBD group showed less decline in anaerobic fitness (peak power) compared to the placebo group.", "population_specificity": "Healthy individuals", "effective_dosage": "50 mg daily (oral capsules)", "study_duration": "8 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:11:56.524479+00:00"}
{"study_id": 50622, "supplement_id": 977, "safety_score": "80", "efficacy_score": 85, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the safety and efficacy of a combined 5-fluorouracil (5-FU) and cannabidiol (CBD)-loaded nanostructured lipid carrier gel (FU-CBD-NLCs gel) for treating non-melanoma skin cancer.", "results_summary": "The study found that FU-CBD NLCs gel showed excellent uptake and deposition in skin layers, was less irritant than conventional treatments, and significantly reduced tumor volume in in-ovo studies. The formulation also improved survival rates and reduced tumor number, area, and volume.", "population_specificity": "Non-melanoma skin cancer (in-ovo model).", "effective_dosage": "Not specified.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:12:01.951120+00:00"}
{"study_id": 50624, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to determine if CBD affects blood pressure and vascular health in hypertensive patients, specifically examining whether serum urotensin-II levels reflect hemodynamic changes caused by CBD.", "results_summary": "CBD supplementation significantly reduced serum urotensin-II levels and correlated with a reduction in 24-hour mean arterial pressure, independent of confounding factors. No such effects were observed with placebo.", "population_specificity": "51 patients with mild to moderate hypertension", "effective_dosage": "Not specified", "study_duration": "5 weeks per intervention (CBD and placebo)", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:12:02.343180+00:00"}
{"study_id": 50625, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to evaluate the therapeutic potential of natural products, including CBD, for treating drug-resistant epilepsy (DRE) and to assess their ethnopharmacological relevance.", "results_summary": "The study found that CBD, among other natural products, shows promise in treating DRE, with potential mechanisms involving vagus nerve activation. It highlights CBD's clinical promise and novel mechanisms of action.", "population_specificity": "Patients with drug-resistant epilepsy (DRE).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:12:03.000861+00:00"}
{"study_id": 50623, "supplement_id": 977, "safety_score": "85", "efficacy_score": 50, "quality_score": 70, "study_goal": "The researchers aimed to determine if CBD could moderate and attenuate the effects of ayahuasca on emotion recognition in facial expressions (REFE) and empathy tasks.", "results_summary": "The study found no evidence of interactive effects between ayahuasca and CBD. Both groups showed reductions in reaction times for REFE and empathy tasks, as well as reductions in anxiety, sedation, cognitive deterioration, and discomfort, but no between-group differences were observed.", "population_specificity": "Seventeen healthy volunteers.", "effective_dosage": "600 mg oral CBD.", "study_duration": "1 week (with follow-ups at 6.5 hours, 1 day, and 7 days post-intervention).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:12:03.060982+00:00"}
{"study_id": 50626, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to review available data on pharmacokinetic drug-drug interactions involving CBD to help clinicians better understand its implications in practice.", "results_summary": "The review identified several pharmacokinetic drug-drug interactions between CBD and different classes of medications, highlighting potential clinical complications due to CBD's widespread but poorly understood pharmacological profile.", "population_specificity": "Not specified (narrative review of existing data)", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "Several pharmacokinetic drug-drug interactions with different medication classes were noted.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:12:03.564989+00:00"}
{"study_id": 50627, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 70, "study_goal": "The researchers aimed to explore the therapeutic potential of phytocannabinoids and synthetic cannabinoids, including CBD, for treating various diseases.", "results_summary": "Preclinical data support the use of cannabinoids for neurological pathologies, pain, cancer, psychiatric disorders, and chemotherapy-induced emetic symptoms, but clinical trial data do not fully support their efficacy for these conditions. More studies are needed to clarify their usefulness.", "population_specificity": "Not specified (broad review of preclinical and clinical studies)", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:12:03.701292+00:00"}
{"study_id": 50629, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to explore the potential of exosomes as delivery systems for cannabinoids like CBD, focusing on their anticancer properties and role in cancer epigenetics.", "results_summary": "The study highlights CBD's anticancer mechanisms, including cell cycle arrest, proliferation inhibition, and activation of autophagy and apoptosis, as well as its potential in histone modifications and cancer epigenetics. EVs loaded with cannabinoids showed promise for tumor-specific delivery and enhanced anticancer effects.", "population_specificity": "Not specified (review of existing literature on cannabinoids and EVs).", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:12:05.645251+00:00"}
{"study_id": 50628, "supplement_id": 977, "safety_score": "75", "efficacy_score": 30, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the benefits and harms of cannabis-based medicines, including CBD, for treating pain and other symptoms in adults with cancer compared to placebo or other established analgesics.", "results_summary": "The study found moderate-certainty evidence that CBD (as part of oromucosal nabiximols) did not provide clinically relevant benefits for opioid-refractory cancer pain. Low-certainty evidence suggested CBD oil did not enhance pain reduction in advanced cancer patients receiving specialist palliative care.", "population_specificity": "Adults with cancer experiencing moderate-to-severe pain, including those with opioid-refractory pain and advanced cancer.", "effective_dosage": "Not specified for CBD alone; nabiximols (THC+CBD) dosages varied by study.", "study_duration": "Ranged from 2 to 5 weeks for nabiximols/THC trials; 8 weeks for nabilone (synthetic THC analogue).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:12:08.227748+00:00"}
{"study_id": 50635, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the potential mechanisms of CBD in tumor-acquired biological capabilities and propose synergistic drug combinations for future research.", "results_summary": "The abstract suggests CBD has potential tumor-suppressing properties, but the mechanisms remain unclear. Recent studies reveal CBD's role in cancer hallmarks, though inconsistencies and flaws exist in current research.", "population_specificity": "Not specified (general cancer research context).", "effective_dosage": "Not mentioned.", "study_duration": "Not mentioned.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:12:12.438868+00:00"}
{"study_id": 50631, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 20, "quality_score": 30, "study_goal": "The researchers aimed to review emergent treatments, including CBD, for bipolar disorder (BD) depression and assess their efficacy based on available evidence.", "results_summary": "The study found no adequately powered randomized controlled trials (RCTs) to support the use of CBD in BD depression, indicating insufficient evidence for its efficacy in this context.", "population_specificity": "Individuals with bipolar disorder experiencing depression.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:12:12.534294+00:00"}
{"study_id": 50632, "supplement_id": 977, "safety_score": "70", "efficacy_score": 80, "quality_score": 85, "study_goal": "The researchers aimed to examine the safety and effectiveness of intermittent diazepam nasal spray in patients with seizure clusters who also received CBD treatment.", "results_summary": "The study found that CBD did not alter the safety and effectiveness of diazepam nasal spray, with the lowest rates of treatment-emergent adverse events and second doses (proxy for effectiveness) observed in the highly purified CBD group.", "population_specificity": "Patients aged 6 to 65 years with seizure clusters, including those with epileptic encephalopathies like Dravet syndrome or Lennox-Gastaut syndrome.", "effective_dosage": "Age- and weight-based dosing of diazepam nasal spray (specific amounts not detailed).", "study_duration": "12-month treatment period.", "interactions": "Concomitant use with clobazam was noted, but no significant adverse interactions were reported.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:12:12.891830+00:00"}
{"study_id": 50634, "supplement_id": 977, "safety_score": "85", "efficacy_score": 80, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the efficacy and tolerability of add-on CBD in treatment-resistant patients with epilepsy with myoclonic-atonic seizures (EMAtS) and Sturge Weber syndrome (SWS) with myoclonic-atonic seizures.", "results_summary": "The study found that 57.7% of patients had a >50% seizure reduction, with 11.5% becoming seizure-free, and the remaining 42.3% experiencing a 25-50% reduction. Side effects were mild and did not lead to discontinuation.", "population_specificity": "Children with treatment-resistant EMAtS (n=22) or SWS with myoclonic-atonic seizures (n=4).", "effective_dosage": "8 to 40 mg/kg/day.", "study_duration": "Mean follow-up of 19 months.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:12:13.398079+00:00"}
{"study_id": 50633, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 85, "study_goal": "The researchers aimed to investigate the impact of 28-day adjunctive CBD treatment on brain function and metabolism in recent-onset psychosis patients.", "results_summary": "The study suggested CBD's potential as an effective and well-tolerated antipsychotic agent, though the neurobiological mechanisms remained unclear. Brain function and metabolism changes were assessed via MRI and spectroscopy.", "population_specificity": "31 stable recent-onset psychosis patients (<5 years after diagnosis).", "effective_dosage": "600 mg daily", "study_duration": "28 days", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:12:14.375198+00:00"}
{"study_id": 50637, "supplement_id": 977, "safety_score": "85", "efficacy_score": 75, "quality_score": 70, "study_goal": "The researchers aimed to evaluate the therapeutic potential of CBD in musculoskeletal (MSK) regenerative medicine, focusing on its immunomodulatory, anti-inflammatory, and tissue-regenerative properties.", "results_summary": "CBD demonstrated significant potential in modulating mammalian tissue to attenuate chronic MSK disorders, with effects including immunomodulation, stimulation of cell activity (especially in mesenchymal stem cells), and tissue regeneration. No serious adverse effects were reported, and CBD was considered safe and well-tolerated.", "population_specificity": "Patients with chronic musculoskeletal disorders (e.g., osteoarthritis, rheumatoid arthritis, back pain, myofascial pain syndrome).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:12:15.014188+00:00"}
{"study_id": 50636, "supplement_id": 977, "safety_score": "85", "efficacy_score": 70, "quality_score": 80, "study_goal": "The researchers aimed to compare the effectiveness of CBD, alone or combined with minor cannabinoids, versus melatonin for improving sleep disturbance in adults.", "results_summary": "All CBD formulations were safe and improved sleep disturbance, but the effects did not surpass those of 5 mg melatonin. Adding minor cannabinoids (CBN, CBC) did not enhance the efficacy of CBD or melatonin.", "population_specificity": "1,793 adults experiencing symptoms of sleep disturbance.", "effective_dosage": "15 mg CBD or 5 mg melatonin, alone or with minor cannabinoids (capsules).", "study_duration": "4 weeks.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:12:15.786643+00:00"}
{"study_id": 50638, "supplement_id": 977, "safety_score": "85", "efficacy_score": 75, "quality_score": 90, "study_goal": "The researchers aimed to evaluate the effect of steady-state CBD exposure on the pharmacokinetics of everolimus in healthy adults.", "results_summary": "The study found that CBD increased everolimus systemic exposure by approximately 2.5-fold without significantly altering its half-life. Everolimus was well tolerated when coadministered with CBD, but monitoring and dose adjustments were advised.", "population_specificity": "Healthy adult participants", "effective_dosage": "CBD at 12.5 mg/kg twice daily (morning and evening)", "study_duration": "9 days (days 9-17)", "interactions": "Increased everolimus systemic exposure when coadministered with CBD", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:12:16.764157+00:00"}
{"study_id": 50640, "supplement_id": 977, "safety_score": "85", "efficacy_score": 65, "quality_score": 70, "study_goal": "The researchers aimed to evaluate preclinical and clinical data on CBD's potential to treat cognitive impairment associated with disorders like schizophrenia, epilepsy, and Alzheimer's disease.", "results_summary": "Preclinical studies showed CBD improved cognitive performance, but clinical studies did not confirm this effect. More research is needed to determine CBD's efficacy as a monotherapy for cognitive dysfunction.", "population_specificity": "Preclinical (animal) and limited controlled human studies, focusing on cognitive impairment in disorders like schizophrenia, epilepsy, and Alzheimer's.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:12:21.322754+00:00"}
{"study_id": 50641, "supplement_id": 977, "safety_score": "85", "efficacy_score": 75, "quality_score": 70, "study_goal": "The researchers aimed to meta-analyze the evidence for anxiety-reduction by compounds facilitating endocannabinoid signaling, focusing on CBD, and identify potential moderators of its effects.", "results_summary": "The study found that CBD showed pooled positive effects on both conditioned and unconditioned anxiety in animals and experimentally induced anxiety in humans, with larger effects observed when anxiety pre-existed. However, evidence quality was low with indications of publication bias.", "population_specificity": "Animals (114 studies) and humans (6 studies).", "effective_dosage": "Not specified.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:12:21.416356+00:00"}
{"study_id": 50643, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 80, "study_goal": "The researchers aimed to determine whether CBD affects plasma anandamide levels in individuals with cannabis use disorder and whether these changes correlate with clinical outcomes.", "results_summary": "The study found that 800 mg/day CBD modulated anandamide levels compared to placebo, while 400 mg/day showed no effect. Changes in anandamide levels were not associated with clinical outcomes like cannabis use, withdrawal, anxiety, or depression.", "population_specificity": "Individuals meeting criteria for cannabis use disorder and attempting cannabis cessation.", "effective_dosage": "400 mg/day and 800 mg/day CBD.", "study_duration": "28 days.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:12:22.195703+00:00"}
{"study_id": 50639, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 80, "study_goal": "The researchers aimed to determine the impact of a standardized 1 mL sublingual dose of CannEpil on driving performance and ocular behavior in healthy licensed drivers.", "results_summary": "CannEpil did not significantly alter standard deviation of lateral position (SDLP) overall but increased SDLP between 20-30 minutes. It impaired select aspects of vehicle control (speed and weaving) over time and altered ocular behavior, suggesting eye tracking may help assess cannabis-related driver impairment.", "population_specificity": "31 healthy fully licensed drivers (15 male, 16 female) aged 21-58 years.", "effective_dosage": "1 mL sublingual dose.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:12:22.481090+00:00"}
{"study_id": 50644, "supplement_id": 977, "safety_score": "40", "efficacy_score": 70, "quality_score": 80, "study_goal": "The researchers aimed to investigate the frequency and risk of adverse events (AEs) associated with CBD use in patients with epilepsy.", "results_summary": "The study found that CBD use in epilepsy patients was associated with a higher incidence of adverse events (9.7% in CBD group vs. 4.0% in control group) and increased risks for serious AEs, discontinuation, and dose reduction. The findings suggest caution due to potential bias in included studies.", "population_specificity": "Patients with epilepsy.", "effective_dosage": "Not specified in the abstract.", "study_duration": "Not specified in the abstract.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:12:22.762269+00:00"}
{"study_id": 50646, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 70, "study_goal": "The researchers aimed to develop and test CannaCount, a metric to quantify estimated maximum possible exposure to THC and CBD in medical cannabis patients.", "results_summary": "The study demonstrated that CannaCount could estimate THC and CBD exposure in most study visits, with improved accuracy over time due to better product labeling and consumer awareness. The abstract does not report specific effects of CBD.", "population_specificity": "60 medical cannabis patients enrolled in a two-year longitudinal observational study.", "effective_dosage": "Not specified", "study_duration": "Two years", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:12:23.479618+00:00"}
{"study_id": 50648, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 70, "study_goal": "The researchers aimed to collect preclinical and clinical evidence about the effects of cannabidiol (CBD), particularly focusing on its long-term effects, especially in adolescence.", "results_summary": "The abstract highlights that CBD has anxiolytic and antipsychotic properties, contrasting with THC's psychoactive effects, but notes a lack of information on long-term effects, particularly in adolescents.", "population_specificity": "General population, with specific mention of adolescents.", "effective_dosage": "Not available", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:12:24.255137+00:00"}
{"study_id": 50647, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 65, "study_goal": "The researchers aimed to evaluate the potential of CBD-loaded solid lipid nanoparticles (SLN) tailored with tocilizumab (TCZ) for oral administration as a treatment for COVID-19, focusing on its anti-inflammatory and immunomodulatory effects.", "results_summary": "The study proposed that CBD, combined with TCZ in SLN, could modulate inflammation and ACE2 expression, potentially mitigating cytokine storms in COVID-19 patients. CBD was noted for its anti-inflammatory, anti-cancer, and mental health benefits, but clinical outcomes were not explicitly detailed.", "population_specificity": "Patients infected with SARS-CoV-2, particularly those experiencing cytokine storms or hyperinflammatory phases.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:12:25.459246+00:00"}
{"study_id": 50652, "supplement_id": 977, "safety_score": "30", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to summarize how phytocannabinoids, including CBD, impact placental development and function, focusing on receptor actions and placental vulnerability.", "results_summary": "The study found that prenatal cannabinoid exposure, including CBD, may significantly impact placental development, leading to compromised vasculature and function, which is associated with fetal growth restriction.", "population_specificity": "Pregnant individuals and murine models.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:12:30.367590+00:00"}
{"study_id": 50649, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 75, "study_goal": "The researchers aimed to investigate the use of nanomaterial-based electrochemical sensing for detecting CBD and \u03949-THC, focusing on improving sensor sensitivity and selectivity.", "results_summary": "The study explored how nanomaterials can be functionalized to enhance electrochemical sensors for CBD and \u03949-THC detection, examining factors like sensor pretreatment and physiochemical parameters (e.g., pH) that influence performance. It proposed guidelines for developing point-of-care sensors for these cannabinoids.", "population_specificity": "Not specified (laboratory-based research)", "effective_dosage": "Not mentioned", "study_duration": "Not mentioned", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:12:30.452754+00:00"}
{"study_id": 50650, "supplement_id": 977, "safety_score": "85", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the neuroprotective potential of CBD and its therapeutic effects in managing neurological disorders such as Alzheimer's disease, Parkinson's disease, and epilepsy.", "results_summary": "The study found that CBD has significant neuropharmacological effects, including reducing neuroinflammation, protein misfolding, and oxidative stress, without causing psychotropic effects. It highlights CBD's potential as a supplementary treatment for neurological diseases, supported by ongoing clinical trials.", "population_specificity": "Not specified (review article, not a clinical study)", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:12:30.506671+00:00"}
{"study_id": 50651, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 80, "study_goal": "The researchers aimed to review current scientific research on the efficacy of CBD for seizure, anxiety, osteoarthritis, and atopic dermatitis, while also discussing the endocannabinoid system, molecular mechanisms, and potential side effects in veterinary medicine.", "results_summary": "The abstract highlights CBD's potential anticancer, antiangiogenic, anti-inflammatory, and antiseizure properties in in vitro and in vivo models, with cautious optimism for its use in dogs alongside other therapeutics for various disorders. However, scientific evidence in dogs remains limited.", "population_specificity": "Primarily focused on veterinary medicine (dogs), with broader implications from in vitro and in vivo models.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:12:31.472403+00:00"}
{"study_id": 50656, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 50, "quality_score": 70, "study_goal": "The researchers aimed to review known and possible interactions between cannabinoids (including CBD) and therapies for triple-negative breast cancer (TNBC).", "results_summary": "The abstract highlights mixed findings, with some preclinical studies suggesting antitumor activities of CBD and other cannabinoids, while others indicate potential tumor progression. Clinical studies on cannabinoids in cancer patients remain limited.", "population_specificity": "Triple-negative breast cancer (TNBC) cells and patients, though clinical data are sparse.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:12:32.756436+00:00"}
{"study_id": 50657, "supplement_id": 977, "safety_score": "75", "efficacy_score": null, "quality_score": 65, "study_goal": "The researchers aimed to review the tolerance profile and legislative status of CBD and THC for therapeutic purposes in France.", "results_summary": "The study found that CBD has a reassuring tolerability profile during chronic use but carries a significant risk of drug interactions. THC was associated with more serious adverse effects, particularly neuropsychological and cardiovascular effects.", "population_specificity": "Not specified (review of existing literature and legal texts).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "Significant risk of drug interactions mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:12:33.173807+00:00"}
{"study_id": 50653, "supplement_id": 977, "safety_score": "85", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to update the understanding of CBD-related toxicity and adverse events in humans, focusing on clinical studies conducted between 2019 and 2022.", "results_summary": "The study found that CBD is generally well tolerated, with most adverse events being mild or moderate, such as diarrhea and somnolence. Few serious adverse events were reported, particularly when CBD was co-administered with medications like clobazam and valproate.", "population_specificity": "Adults and children, primarily those with neurological conditions (e.g., treatment-resistant epilepsies) and psychopathological conditions (e.g., substance use disorders, chronic psychosis, anxiety).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "Co-administration with clobazam and valproate may increase the risk of serious adverse events.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:12:33.780285+00:00"}
{"study_id": 50655, "supplement_id": 977, "safety_score": "65", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to determine a point of departure for CBD's potential hepatotoxic effects using human HepaRG spheroid cultures and transcriptomic benchmark dose analysis.", "results_summary": "CBD treatment resulted in EC50 concentrations for cytotoxicity at 86.27 \u00b5M (24h) and 58.04 \u00b5M (72h), with minimal gene and pathway alterations below 10 \u00b5M. At 72h, CBD suppressed immune-regulation-associated genes, aligning with known immune-modulatory effects of CBD.", "population_specificity": "Human HepaRG spheroid cultures (in vitro liver cell model).", "effective_dosage": "10 \u00b5M (low concentration), 58.04 \u00b5M (72h EC50), 86.27 \u00b5M (24h EC50).", "study_duration": "24 and 72 hours.", "interactions": "Potential drug-drug interactions with valproate and clobazam (mentioned in abstract context but not directly tested in this study).", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:12:34.753525+00:00"}
{"study_id": 50660, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to determine if 5-week administration of CBD reduces blood pressure in hypertensive patients and explore the mechanistic role of catestatin in this effect.", "results_summary": "CBD administration reduced serum catestatin levels and showed a strong correlation with mean arterial pressure reduction, suggesting CBD's antihypertensive effects may involve the sympatho-chromaffin system.", "population_specificity": "54 patients with Grade 1 hypertension", "effective_dosage": "Not specified", "study_duration": "5 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:12:37.993692+00:00"}
{"study_id": 50659, "supplement_id": 977, "safety_score": "90", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to evaluate the clinical safety and efficacy of topical 0.1% CBD for managing recurrent aphthous ulcers (RAUs).", "results_summary": "Topical 0.1% CBD significantly reduced ulcer size and accelerated healing without side effects, demonstrating anti-inflammatory effects early and analgesic effects later. CBD performed comparably to triamcinolone acetonide (TA) in reducing ulcer size and pain, with higher patient satisfaction than placebo.", "population_specificity": "Healthy subjects (100 for patch test, 50 for safety) and 69 RAU patients.", "effective_dosage": "0.1% CBD applied topically 3 times/day.", "study_duration": "7 days.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:12:39.636085+00:00"}
{"study_id": 184950, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 50, "study_goal": "The researchers aimed to investigate whether 3 weeks of daily CBD supplementation (150 mg/day) could influence exercise performance by potentially modulating pain perception.", "results_summary": "The abstract does not provide results regarding CBD's effects on exercise performance or pain perception.", "population_specificity": "Not specified in the abstract.", "effective_dosage": "150 mg/day", "study_duration": "3 weeks", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:12:39.776822+00:00"}
{"study_id": 184949, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to evaluate the effects of CBD on exercise capacity and post-load recovery in physically active individuals.", "results_summary": "The study found limited beneficial effects of CBD on physiological parameters like VO2, mean power, and relative mean power, but minimal impact on strength parameters and post-load recovery. Most studies were recent (2021-2024), indicating growing research interest.", "population_specificity": "Healthy, physically active individuals (professional athletes not specified).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:12:40.693226+00:00"}
{"study_id": 184952, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": null, "quality_score": 50, "study_goal": "The researchers aimed to highlight concerns about the safety, efficacy, and regulatory oversight of natural medicines, using CBD as an example.", "results_summary": "The abstract notes that evidence for the effectiveness and safety of natural medicines, including CBD, is often poor, with issues like poor manufacturing, contamination, and mislabeling identified. It calls for regulatory reform and better clinician education.", "population_specificity": "Not specified", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:12:41.746953+00:00"}
{"study_id": 184953, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 20, "quality_score": 85, "study_goal": "The researchers aimed to determine whether topical CBD provided additional pain relief, reduced opioid use, or improved sleep scores in patients following total knee arthroplasty (TKA).", "results_summary": "The study found no statistically significant benefits of topical CBD in reducing pain, opioid consumption, or improving sleep scores after TKA compared to placebo or essential oil treatments. The CBD group even showed higher pain scores on postoperative day 2 compared to the essential oil group.", "population_specificity": "Patients undergoing primary unilateral total knee arthroplasty (TKA).", "effective_dosage": "Applied thrice daily (specific CBD dosage not mentioned).", "study_duration": "Two weeks postoperatively.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:12:43.902729+00:00"}
{"study_id": 50661, "supplement_id": 977, "safety_score": "40", "efficacy_score": 70, "quality_score": 85, "study_goal": "The researchers aimed to compare the pharmacokinetics and pharmacodynamics of orally administered \u03949-THC-dominant and CBD-dominant cannabis extracts containing the same \u03949-THC dose (20 mg).", "results_summary": "The study found that a CBD-dominant cannabis extract (20 mg \u03949-THC + 640 mg CBD) produced stronger adverse effects (e.g., increased anxiety, sedation, memory difficulty, heart rate, and cognitive impairment) compared to a \u03949-THC-dominant extract (20 mg \u03949-THC alone), contradicting claims that CBD attenuates \u03949-THC's adverse effects. CBD likely inhibited \u03949-THC metabolism, leading to higher plasma concentrations of \u03949-THC and its metabolites.", "population_specificity": "18 healthy adults (11 males, 7 females; mean age 30 years) with no cannabis use for at least 30 days prior to the study.", "effective_dosage": "20 mg \u03949-THC (with 0 mg or 640 mg CBD), administered once per session.", "study_duration": "Three experimental sessions, each separated by at least 1 week.", "interactions": "Interaction with a cytochrome P450 (CYP) probe drug cocktail (caffeine, omeprazole, losartan, dextromethorphan, midazolam).", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:12:44.394119+00:00"}
{"study_id": 184955, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 70, "quality_score": 75, "study_goal": "The researchers aimed to review the current evidence on the therapeutic potential of medical cannabis, including CBD, for various conditions, highlighting areas with substantial evidence and those needing further research.", "results_summary": "The study found strong empirical support for CBD in treating intractable childhood epilepsy and multiple sclerosis, while evidence for PTSD and anxiety remains controversial. Real-world evidence (RWE) suggests widespread patient-reported benefits, but randomized controlled trials (RCTs) are needed to bridge the evidence gap.", "population_specificity": "Patients with conditions such as intractable childhood epilepsy, multiple sclerosis, PTSD, and anxiety.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:12:46.915582+00:00"}
{"study_id": 184958, "supplement_id": 977, "safety_score": "Not Assessed", "efficacy_score": 65, "quality_score": 75, "study_goal": "The researchers aimed to compare the bioavailability of water-soluble and lipid-soluble CBD powders and explore their potential acute anti-inflammatory effects in humans.", "results_summary": "The study found differences in pharmacokinetics between the two CBD formulations, with the water-soluble powder showing higher bioavailability. Anti-inflammatory effects were assessed via IL-10 and TNF levels in LPS-stimulated PBMCs, but results were not fully detailed in the abstract.", "population_specificity": "10 healthy adults", "effective_dosage": "Single 30 mg dose", "study_duration": "Single administration with blood sampling over 6 hours", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:12:48.164330+00:00"}
{"study_id": 6076, "supplement_id": 978, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to determine whether cannabinoids are an effective treatment for pain and symptoms associated with peripheral neuropathy.", "results_summary": "Thirteen of 14 studies (79%) reported a statistically significant decrease in neuropathic pain scores with cannabinoid treatment. Meta-analysis showed a mean difference of -0.67 on a 0-10 scale compared to placebo, with improvements in sleep, sensory symptoms, and quality of life.", "population_specificity": "Patients with peripheral neuropathic pain caused by nerve injury, trauma, and other noncompressive etiologies.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:12:48.513502+00:00"}
{"study_id": 6077, "supplement_id": 978, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 90, "study_goal": "The researchers aimed to develop a novel electrochemical sensing platform for detecting cyclohexanylphenol synthetic cannabinoids (CP-type SCs) in e-cigarettes.", "results_summary": "The optimized ZnO-Bi2O3 heterojunction sensor demonstrated high sensitivity, reliability, and detection limits for CP47,497 and CP55,940, enabling effective on-site electrochemical detection in e-cigarettes. The study also explored the electrochemical oxidation mechanisms and fingerprints of CP-type SCs.", "population_specificity": "Not specified (focused on sensor development and detection).", "effective_dosage": "Not applicable (sensor testing, not human dosage).", "study_duration": "Not applicable (laboratory study).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:12:50.080080+00:00"}
{"study_id": 6078, "supplement_id": 978, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 60, "study_goal": "The researchers aimed to explore the potential benefits of combining cannabinoids with chemotherapy to enhance anticancer effects and alleviate chemotherapy-induced adverse effects.", "results_summary": "The study suggests that cannabinoids, particularly non-psychoactive ones like cannabidiol and cannabinol, may synergize with chemotherapy by targeting cancer cells through different mechanisms and alleviating side effects such as immune depression, nausea, and appetite loss. Additionally, combining cannabinoids with calorie restriction or intermittent fasting could further enhance anticancer effects by depriving tumors of glucose.", "population_specificity": "Cancer patients undergoing chemotherapy (not explicitly specified but implied).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:12:51.137213+00:00"}
{"study_id": 6079, "supplement_id": 978, "safety_score": "Not Assessed", "efficacy_score": 85, "quality_score": 80, "study_goal": "The researchers aimed to assess the efficacy of cannabinoids, particularly nabiximols, in controlling spasticity in patients with multiple sclerosis (MS).", "results_summary": "The meta-analysis found that nabiximols significantly reduced spasticity, as measured by the Numeric Rating Scale (NRS) and Ashworth Scale, with pooled standardized mean differences of -1.41 and -0.39, respectively. The study concluded that nabiximols was effective in managing MS-related spasticity.", "population_specificity": "Patients with multiple sclerosis experiencing spasticity (mean Expanded Disability Status Scale ranged between 4.6 and 7).", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:12:53.187082+00:00"}
{"study_id": 6080, "supplement_id": 978, "safety_score": "30", "efficacy_score": 70, "quality_score": 60, "study_goal": "The researchers aimed to summarize the efficacy and safety of cannabinoids for treating obstructive sleep apnea (OSA).", "results_summary": "Eight of nine studies reported statistically significant improvements in OSA outcomes, including reduced apnea hypopnea index and improved daytime sleepiness. However, 70-80% of participants experienced neuropsychiatric and gastrointestinal adverse events.", "population_specificity": "Patients with obstructive sleep apnea (OSA).", "effective_dosage": "Not specified.", "study_duration": "Median duration of 3 weeks (range: 1-6 weeks).", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:12:53.262717+00:00"}
{"study_id": 6081, "supplement_id": 978, "safety_score": "65", "efficacy_score": 50, "quality_score": 70, "study_goal": "The researchers aimed to evaluate the potential mechanisms, efficacy, and adverse effects of cannabinoids in treating glaucoma.", "results_summary": "Cannabinoids lower intraocular pressure, but the effect is short-lived, and there is insufficient evidence to recommend their routine use for glaucoma treatment. The study also highlights the lack of a well-formulated ocular delivery system.", "population_specificity": "Healthy volunteers and patients with glaucoma.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:12:54.886106+00:00"}
{"study_id": 6082, "supplement_id": 978, "safety_score": "Not Assessed", "efficacy_score": 45, "quality_score": 75, "study_goal": "The researchers aimed to determine whether different cannabinoids (delta-9-THC, HU-210, and Anandamide) affect methylation patterns and expression of schizophrenia-related genes involved in synaptic connectivity in a neuron-like cell culture model.", "results_summary": "Cannabinoid treatment resulted in blunted cell morphology and reduced neuronal differentiation markers, with methylation rates and mRNA levels approaching those of undifferentiated controls. No significant differences were observed between the three cannabinoids, but THC notably decreased fluorescence intensity and expression of synaptic targets compared to retinoic acid-treated cells.", "population_specificity": "SH-SY5Y cell culture model (neuron-like cells)", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:12:57.692221+00:00"}
{"study_id": 6083, "supplement_id": 978, "safety_score": "Not Assessed", "efficacy_score": 75, "quality_score": 65, "study_goal": "The researchers aimed to evaluate the role of cannabinoids in managing chronic neuropathic pain and compare their efficacy and risks to opioid therapies.", "results_summary": "The study found evidence supporting the efficacy of cannabinoids for neuropathic pain, with meaningful response rates in select patient populations, though it emphasized the need for multimodal treatment approaches.", "population_specificity": "Patients with chronic neuropathic pain conditions, such as postherpetic neuralgia.", "effective_dosage": "Not specified", "study_duration": "Not specified", "interactions": "None mentioned", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:12:57.733644+00:00"}
{"study_id": 6084, "supplement_id": 978, "safety_score": "60", "efficacy_score": 70, "quality_score": 80, "study_goal": "The researchers aimed to summarize existing literature on cannabinoid receptor expression and their influence on renal function, including potential therapeutic applications and adverse effects on renal and cardiovascular health.", "results_summary": "The study highlights the role of the endocannabinoid system in renal physiology and pathology, noting both therapeutic potential and detrimental effects on kidney function and cardiovascular outcomes. Recent studies identified adverse impacts of cannabinoids on renal and cardiovascular health.", "population_specificity": "Not specified (literature review).", "effective_dosage": "Not mentioned.", "study_duration": "Not mentioned.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:12:58.977132+00:00"}
{"study_id": 6085, "supplement_id": 978, "safety_score": "85", "efficacy_score": 75, "quality_score": 80, "study_goal": "The researchers aimed to explore the therapeutic value of cannabinoids (THC and CBD) in managing chronic pain and improving patients' quality of life.", "results_summary": "Cannabinoids provided significant relief from chronic pain (33% vs 15% placebo) as measured by the visual analog scale, with transdermal CBD showing pronounced reduction in sharp pain. Minimal to no side effects were recorded.", "population_specificity": "Patients with chronic neuropathic pain.", "effective_dosage": "Not specified.", "study_duration": "Not specified.", "interactions": "None mentioned.", "analysis_prompt_version": "1.1", "last_analyzed_at": "2025-06-19T20:12:59.481545+00:00"}
